SPIROPYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE

Abstract
The present invention is directed to spiropyrrolidine compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.
Description
FIELD OF THE INVENTION

The invention is directed to spiropyrrolidine compounds which are useful as inhibitors of the beta secretase enzyme, and are useful in the treatment of diseases in which the beta secretase enzyme is involved, such as Alzheimer's Disease.


BACKGROUND OF THE INVENTION

Alzheimer's disease is characterized by the deposition of amyloid in the brain in the form of extra-cellular plaques and intra-cellular neurofibrillary tangles. The rate of amyloid accumulation is a function of the rates of formation, aggregation and egress from the brain. It is generally accepted that the main constituent of amyloid plaques is the 4 kD amyloid protein (βA4, also referred to as Aβ, β-protein and βAP) which is a proteolytic product of a precursor protein of much larger size. The amyloid precursor protein (APP or AβPP) has a receptor-like structure with a large ectodomain, a membrane spanning region and a short cytoplasmic tail. The Aβ domain encompasses parts of both extra-cellular and transmembrane domains of APP, thus its release implies the existence of two distinct proteolytic events to generate its NH2— and COOH— termini. At least two secretory mechanisms exist which release APP from the membrane and generate soluble, COOH-truncated forms of APP (APPs). Proteases that release APP and its fragments from the membrane are termed “secretases.” Most APPs is released by a putative α-secretase which cleaves within the Aβ protein to release α-APPs and precludes the release of intact Aβ. A minor portion of APPs is released by a β-secretase (“β-secretase”), which cleaves near the NH2-terminus of APP and produces COOH-terminal fragments (CTFs) which contain the whole Aβ domain.


Thus, the activity of β-secretase or β-site amyloid precursor protein-cleaving enzyme (“BACE”) leads to the cleavage of APP, production of Aβ, and accumulation of β-amyloid plaques in the brain, which is characteristic of Alzheimer's disease (see R. N. Rosenberg, Arch. Neurol., vol. 59, September 2002, pp. 1367-1368; H. Fukumoto et al, Arch. Neurol., vol. 59, September 2002, pp. 1381-1389; J. T. Huse et al, J. Biol. Chem., vol 277, No. 18, issue of May 3, 2002, pp. 16278-16284; K. C. Chen and W. J. Howe, Biochem. Biophys. Res. Comm, vol. 292, pp 702-708, 2002). Therefore, therapeutic agents that can inhibit β-secretase or BACE may be useful for the treatment of Alzheimer's disease.


The compounds of the present invention are useful for treating Alzheimer's disease by inhibiting the activity of β-secretase or BACE, thus preventing the formation of insoluble Aβ and arresting the production of Aβ.


SUMMARY OF THE INVENTION

The present invention is directed to spiropyrrolidine compounds of general formula (I)




embedded image


and pharmaceutically acceptable salts thereof, which are useful as inhibitors of the β-secretase enzyme.


The invention is also directed to pharmaceutical compositions which include a therapeutically effective amount of a compound of formula (I), or pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier. The invention is also directed to methods of treating mammals for diseases in which the β-secretase enzyme is involved, such as Alzheimer's disease, and the use of the compounds and pharmaceutical compositions of the invention in the treatment of such diseases.







DETAILED DESCRIPTION OF THE INVENTION

In one embodiment, the present invention is directed to spiropyrrolidine compounds represented by general formula (I)




embedded image


and pharmaceutically acceptable salts thereof, wherein:


V is selected from the group consisting of

    • (1) C, or
    • (2) N, and the dotted line leading to V represents an optional double bond, and is present when V is C and is absent when V is N;


      or V is selected from the group consisting of
    • (1) C, or


(2) N, and the real line and optional dotted line leading to V represent a single bond or an optional double bond, and represent a single bond when V is N;


Q is selected from the group consisting of


(1) ═CR10—,


(2) ═N—,


(3) —(N→O)—,


(4) —O—, or


(5) ═S—;


Y is selected from the group consisting of


(1) ═CR10—,


(2) —CR10═,


(3) ═CR10—CR11═,


(4) ═CR10—N═, or


(5) ═N—CR10=;


Z is selected from the group consisting of


(1) ═CR10—,


(2) —N—,


(3) —O—, or


(4) ═S—;


provided that Q, Y and Z together with V and the neighboring C atom form a fused aromatic 5- or 6-membered ring;


X1-X2 is selected from the group consisting of


(1) —CR10R11—CR12CR13—,


(2) —CR10R11—O—,


(3) —O—CR10R11—,


(4) —CR10R11—NR12—,


(5) —NR12—CR10R11—,


(6) —CR10R11—S(═O)mR12—,


(7) —S(═O)mR12—, CR10R11—,


(8) —CR10R11—CR12CR13—O—,


(9) —CR10R11—NR14CR12R13—,


(10) —CR10R11—O—CR12CR13—,


(11) —CR10R11—CR12CR13NR14—, or


(12) —O—CR10R11—CR12CR13—, or


(13) —S(═O)pR12—CR10R11—;


R1 is selected from the group consisting of

    • (1) hydrogen
    • (2) C1-6alkyl,
    • (3) C2-6 alkenyl,
    • (4) —C3-9 cycloalkyl,
    • (5) —C6-10aryl,
    • (6) heteroaryl group having from 5 to 12 ring atoms, wherein at least one ring atom is a heteroatom selected from the group consisting of nitrogen, sulfur or oxygen,
    • (7) a heterocyclic group having 4 to 8 ring atoms, wherein at least one ring atom is a heteroatom selected from the group consisting of nitrogen, sulfur or oxygen,
    • wherein said alkyl, alkenyl, aryl, cycloalkyl, heterocyclic or heteroaryl R1 moiety is optionally substituted with one or more
      • (a) halo,
      • (b) —OH,
      • (c) —CN,
      • (d) —C1-6 alkyl,
      • (e) —C3-8 cycloalkyl,
      • (f) —O—C1-6 alkyl,
      • (g) —O—CH2—C6-10aryl,
      • (h) —C6-10aryl,
      • (i) heteroaryl group having from 5 to 12 ring atoms, wherein at least one ring atom is a heteroatom selected from the group consisting of nitrogen, sulfur or oxygen,
      • (j) oxo,
      • (k) a heterocyclic group having 4 to 8 ring atoms, wherein at least one ring atom is a heteroatom selected from the group consisting of nitrogen, sulfur or oxygen,
      • (l) —O—CH2—C3-8 cycloalkyl,
      • (m) —C(═O)—C1-6 alkyl, or
      • (n) —NR5AR5B,


        R2 and R3 are independently selected from the group consisting of:
    • (1) hydrogen,
    • (2) OH,
    • (3) —C1-6 alkyl,
    • (4) —CN,
    • (5) —C6-10 aryl, or
    • (6) heteroaryl group having from 5 to 12 ring atoms, wherein at least one ring atom is a heteroatom selected from the group consisting of nitrogen, sulfur or oxygen,
    • wherein said alkyl, aryl or heteroaryl R2 or R3 moiety is optionally substituted with one or more
      • (a) halo,
      • (b) —C1-6 alkyl, wherein said alkyl is optionally substituted with one or more halogen, and
      • (c) —O—C1-6 alkyl,


        or R2 and R3 are linked together to form cyclic group of 4-10 ring carbon atoms, wherein one or two of the ring carbon atoms is replaced by an oxygen, nitrogen or sulfur;


        R5A and R5B are independently selected from the group consisting of
    • (1) hydrogen,
    • (2) —C1-6 alkyl,
    • (3) —C(═O)—(O)m—C1-6 alkyl,
    • (4) —C(═O)—(O)m—C6-10 aryl,
    • (5) —SO2—C3-8 cycloalkyl,
    • (6) —SO2—C1-6 alkyl,
    • (4) —C(═O)—NR6AR6B, wherein R6A and R6B are selected from the group consisting of wherein the alkyl, cycloalkyl or aryl moiety is optionally substituted with one or more
      • (a) halogen,
      • (b) hydroxyl,
      • (c) —O—C1-6 alkyl, or
      • (d) —C(═O)—(O)m—C1-6 alkyl,
    • or R6A and R6B are linked together with the nitrogen to which they are attached to form a 4-6 membered carbocyclic ring, wherein one or two of the ring carbon atoms is optionally replaced by a nitrogen, oxygen or sulfur, and the ring is optionally substituted with one or more
      • (a) halogen,
      • (b) hydroxyl,
      • (c) C1-6 alkyl,
      • (d) —O—C1-6 alkyl,
      • (e) —C(═O)—(O)m—C1-6 alkyl, or
      • (f) —SO2—C1-6 alkyl;


        R10, R11, R12, R13 and R14 are independently selected from the group consisting of:


(1) hydrogen,


(2) —C1-6 alkyl,


(3) hydroxyl,


(4) —(CH2)m C6-10aryl


(5) —C2-6 alkenyl,


(6) —O—C1-6alkyl,


(7) halogen,


(8) —SO2—C1-6 alkyl,


(9) —NR5AR5B,


(10) —C3-8 cycloalkyl,


(11) —C(═O)—(O)m—C1-6 alkyl,


(12) —C(═O)—(O)m—C6-10 aryl,


(13) —C(═O)—NH—C1-6 alkyl,


(14) —S(═O)2—C6-10 aryl,

    • wherein said alkyl, cycloalkyl, alkenyl or aryl moiety is optionally substituted with one or more
      • (a) halo,
      • (b) hydroxyl,
      • (c) —C1-6 alkyl,
      • (d) —NR5AR5B,
      • (e) —O—C1-6 alkyl, and
      • (f) —C6-10aryl,
    • wherein said wherein said alkyl or aryl is optionally substituted with one or more halo,
    • or any R10 and R11, or any R12 and R13, on identical carbon ring atoms, are linked together to form an oxo group,
    • or any R10 and R11, or any R12 and R13, on identical carbon ring atoms, are linked together to form an aromatic or non-aromatic spirocyclic group of 5-10 ring carbon atoms, wherein one or two of the ring carbon atoms is replaced by an oxygen, nitrogen or sulfur,
      • or any R10 and R11, or any R12 and R13, on adjacent carbon ring atoms, are linked together to form to form a fused aromatic or non-aromatic cyclic group of 5-10 ring carbon atoms, wherein one or two of the ring carbon atoms is replaced by an oxygen, nitrogen or sulfur,


        m is 0 or 1;


        n is 0 or 1;


        p is 0, 1 or 2;


        and pharmaceutically acceptable salts thereof


In particular embodiments of the compounds of formula (I), V is C and the dotted line leading to V represents a double bond. In other embodiments of the compounds of formula (I), V is n and the dotted line leading to V is absent.


In particular embodiments of the compounds of formula (I), -Q-Y—Z— together form the group —CR10═CR10—CR11═CR10—, thereby forming a fused phenyl ring.


In other embodiments of the compounds of formula (I), -Q-Y—Z— together forms the groups —N═CR10—CR11═CR10— or —CR10═CR10—CR11═N—, thereby forming a fused pyridyl ring.


In other embodiments of the compounds of formula (I), -Q-Y—Z— together forms the group —N═CR10—CR11═N— or —N═CR10—N═CR11—, thereby forming a fused pyrimidinyl ring.


In other embodiments of the compounds of formula (I), -Q-Y—Z— together forms the group —NH—CR10═CR10—, —S—CR10═CR10—, —O—CR10═CR10—, N═CR10—S—, —CR10═CR10═S— or —CR10═CR10—O—, thereby forming a five-membered heteroaryl ring.


In particular embodiments of the compounds of formula (I), X1-X2 is —CR10R11— CR12CR13— and n is 0 or 1.


In other embodiments, X1-X2 is —NR12—CR10R11— or —CR10R11—NR12— and n is 1.


In other embodiments, X1-X2 is —S(═O)pR12—CR10R11— and n is 1.


In other embodiments, X1-X2 is —CR10R11—O— or —O—CR10R11— and n is 1.


In other embodiments, X1-X2 is one of —CR10R11—NR14CR12R13—, —CR10R11—O—CR12CR13—, —CR10R11—CR14CR12NR13—, or —O—CR10R11—CR12CR13—.


In particular embodiments of the compounds of formula (I), R1 is selected from the group consisting of

    • (1) hydrogen
    • (2) C1-6alkyl,
    • (3) C3-9 cycloalkyl, or
    • (4) phenyl,
    • wherein said alkyl, cycloalkyl or phenyl R1 moiety is optionally substituted with one or more
      • (a) halo,
      • (b) —OH,
      • (c) —CN,
      • (d) —C1-6 alkyl
      • (e) —C3-6 cycloalkyl, or
      • (f) —O—C1-6 alkyl.


In particular embodiments, R1 is hydrogen, phenyl (optionally substituted with halogen), or cyclohexyl.


In particular embodiments of the compounds of formula (I), R2 is hydrogen and R3 is selected from the group consisting of:


(1) hydrogen,


(2) C6-10aryl (for example, phenyl), or


(3) heteroaryl,


wherein said aryl or heteroaryl R3 moiety is optionally substituted with one or more

    • (a) halo,
    • (b) —C1-6 alkyl, wherein said alkyl is optionally substituted with one or more halogen, and
    • (c) —O—C1-6 alkyl.


In particular embodiments, R2 is hydrogen and R3 is hydrogen or unsubstituted phenyl.


In other embodiments, R2 and R3 are linked together to form cyclic group of 4-10 ring carbon atoms, wherein one or two of the ring carbon atoms is replaced by an oxygen, nitrogen or sulfur.


The invention is also directed to methods of treating mammals for diseases in which the β-secretase enzyme is involved, such as Alzheimer's disease, by administering a therapeutically effective amount of a compound of any of the embodiments of formula (I).


The invention is also directed to pharmaceutical compositions which include an effective amount of a compound of any of the embodiments of formula (I) or pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier.


The invention is further directed to a method for the manufacture of a medicament or a composition for inhibiting β-secretase enzyme activity in humans and animals comprising combining a compound of any of the embodiments of formula (I) or a pharmaceutically acceptable salt thereof, with a pharmaceutical carrier or diluent.


In one embodiment, the invention is directed to methods of inhibiting BACE1 enzyme activity, by administering a therapeutically effective amount of a compound of any of the embodiments of formula (I).


In another embodiment, the invention is directed to methods of inhibiting BACE2 enzyme activity, by administering a therapeutically effective amount of a compound of any of the embodiments of formula (I).


The invention is also directed to a method for the manufacture of a medicament or a composition for treating Alzheimer's Disease in humans, comprising combining a compound of any of the embodiments of formula (I) or a pharmaceutically acceptable salt thereof, with a pharmaceutical carrier or diluent.


In some embodiments, the compound of formula (I) is a compound of formula (II)




embedded image


and pharmaceutically acceptable salts thereof, wherein R2, R5, X1, X2, Q, Y and Z are as defined above.


In particular embodiments of the compounds of formula (II), -Q-Y—Z— together form the group —CR10═CR10—CR11═CR10—, thereby forming a fused phenyl ring.


In other embodiments of the compounds of formula (II), -Q-Y—Z— together forms the groups —N═CR10—CR11═CR10— or —CR10═CR10—CR11═N—, thereby forming a fused pyridyl ring.


In other embodiments of the compounds of formula (II), -Q-Y—Z— together forms a the group —N═CR10—CR11═N— or —N═CR10—N═CR11—, thereby forming a fused pyrimidinyl ring.


In other embodiments of the compounds of formula (II), -Q-Y—Z— together forms the group —NH—CR10═CR10—, —S—CR10═CR10—, —O—CR10═CR10—, —N═CR10—S—, —CR10═CR10═S— or —CR10═CR10—O—, thereby forming a five-membered heteroaryl ring.


In particular embodiments of the compounds of formula (II), X1-X2 is —CR10R11—CR12CR13— and n is 0 or 1.


In other embodiments of the compounds of formula (II), X1-X2 is —NR12—CR10R11— or —CR10R11—NR12— and n is 1.


In other embodiments of the compounds of formula (II), X1-X2 is —S(═O)pR12—CR10R11— and n is 1.


In other embodiments of the compounds of formula (II), X1-X2 is —CR10R11—O— or —O—CR10R11—, and n is 0 or 1.


In other embodiments of the compounds of formula (II), X1-X2 is one of —CR10R11—NR14CR12R13—, —CR10R11—O—CR12CR13—, —CR10R11—CR14CR12NR13—, or —O—CR10R11—CR12CR13—.


In particular embodiments of the compounds of formula (II), R2 is hydrogen and R3 is selected from the group consisting of:


(1) hydrogen,


(2) aryl (for example, phenyl), or


(3) heteroaryl,


wherein said aryl or heteroaryl R3 moiety is optionally substituted with one or more

    • (a) halo,
    • (b) —C1-6 alkyl, wherein said alkyl is optionally substituted with one or more halogen, and
    • (c) —O—C1-6 alkyl.


In particular embodiments of the compounds of formula (II), R2 is hydrogen and R3 is hydrogen or unsubstituted phenyl.


In some embodiments, the compound of formula (I) is a compound of formula (III)




embedded image


and pharmaceutically acceptable salts thereof wherein R2, R5, X2, Q, Y and Z are as defined above.


In particular embodiments of the compounds of formula (III), -Q-Y—Z— together form the group —CR10═CR10—CR11═CR10—, thereby forming a fused phenyl ring.


In other embodiments of the compounds of formula (III), -Q-Y—Z— together forms the groups —N═CR10—CR11═CR10— or —CR10═CR10—CR11═N—, thereby forming a fused pyridyl ring.


In other embodiments of the compounds of formula (III), -Q-Y—Z— together forms the group —N═CR10—CR11═N— or —N═CR10—N═CR11—, thereby forming a fused pyrimidinyl ring.


In other embodiments of the compounds of formula (III), -Q-Y—Z— together forms the group —NH—CR10═CR10—, —S—CR10═CR10—, —O—CR10═CR10—, —N═CR10—S—, —CR10═CR10═S— or —CR10═CR10—O—, thereby forming a five-membered heteroaryl ring.


In particular embodiments of the compounds of formula (III), X1-X2 is —CR10R11—CR12CR13— and n is 0 or 1


In other embodiments of the compounds of formula (III), X1-X2 is —NR12—CR10R11— or —CR10R11—NR12— and n is 1.


In other embodiments of the compounds of formula (III), X1-X2 is —S(═O)pR12—CR10R11— and n is 1.


In other embodiments of the compounds of formula (III), X1-X2 is —CR10R11—O— or —O—CR10R11—, and n is 1.


In other embodiments of the compounds of formula (III), X1-X2 is one of —CR10R11—NR14CR12R13—, —CR10R11—O—CR12CR13—, —CR10R11—CR14CR12NR13—, or —O—CR10R11—CR12CR13.


In some embodiments, the compound of formula (I) is a compound of formula (IV)




embedded image


and pharmaceutically acceptable salts thereof, wherein R2, R3, R4, R5, X1 and X2 are as defined above.


In particular embodiments of the compounds of formula (IV), X1-X2 is —CR10R11—CR12CR13— and n is 0 or 1.


In other embodiments of the compounds of formula (IV), X1-X2 is NR12—CR10R11— or —CR10R11—NR12— and n is 1.


In other embodiments of the compounds of formula (IV), X1-X2 is —S(═O)pR12—CR10R11— and n is 1.


In other embodiments of the compounds of formula (IV), X1-X2 is —CR10R11—O— or —O—CR10R11—, and n is 1 or 2.


In other embodiments of the compounds of formula (IV), X1-X2 is one of —CR10R11—NR14CR12R13—, —CR10R11—O—CR12CR13—, —CR10R11—CR14CR12NR13—, or —O—CR10R11—CR12CR13—.


In particular embodiments of the compounds of formula (IV), R1 is selected from the group consisting of


(1) hydrogen


(2) C1-6alkyl,


(3) C3-6 cycloalkyl, or


(4) phenyl,

    • wherein said alkyl, cycloalkyl or phenyl R1 moiety is optionally substituted with one or more
    • (a) halo,
    • (b) —OH,
    • (c) —CN,
    • (d) —C1-6 alkyl
    • (e) —C3-6 cycloalkyl, or
    • (f) —O—C1-6 alkyl.


In particular embodiments of the compounds of formula (IV), R1 is hydrogen, phenyl (optionally substituted with halogen), or cyclohexyl.


In particular embodiments of the compounds of formula (IV), R2 is hydrogen and R3 is selected from the group consisting of:


(1) hydrogen,


(2) aryl (for example, phenyl), or


(3) heteroaryl,


wherein said aryl or heteroaryl R3 moiety is optionally substituted with one or more

    • (a) halo,
    • (b) —C1-6 alkyl, wherein said alkyl is optionally substituted with one or more halogen, and
    • (c) —O—C1-6 alkyl.


In particular embodiments of the compounds of formula (IV), R2 is hydrogen and R3 is hydrogen or unsubstituted phenyl.


In other embodiments of the compounds of formula (IV), R2 and R3 are linked together to form cyclic group of 4-10 ring carbon atoms, wherein one or two of the ring carbon atoms is replaced by an oxygen, nitrogen or sulfur.


In some embodiments, the compound of formula (I) is a compound of formula (V)




embedded image


and pharmaceutically acceptable salts thereof, wherein R2, R3, R4, R5, X1 and X2 are as defined above.


In particular embodiments of the compounds of formula (V), X1-X2 is —CR10R11—CR12CR13— and n is 0 or 1


In other embodiments of the compounds of formula (V), X1-X2 is —NR12—CR10R11— or —CR10R11—NR12— and n is 1.


In other embodiments of the compounds of formula (V), X1-X2 is —S(═O)pR12—CR10R11— and n is 1.


In other embodiments of the compounds of formula (V), X1-X2 is —CR10R11—O— or —O—CR10R11—, and n is 1.


In other embodiments of the compounds of formula (V), X1-X2 is one of —CR10R11—NR14CR12R13—, —CR10R11—O—CR12CR13—, —CR10R11—CR14CR12NR13—, or —O—CR10R11—CR12CR13—.


In particular embodiments of the compounds of formula (V), R1 is selected from the group consisting of


(1) hydrogen


(2) C1-6alkyl,


(3) C3-6 cycloalkyl, or


(4) phenyl,


wherein said alkyl, cycloalkyl or phenyl R1 moiety is optionally substituted with one or more

    • (a) halo,
    • (b) —OH,
    • (c) —CN,
    • (d) —C1-6 alkyl
    • (e) —C3-6 cycloalkyl, or
    • (f) —O—C1-6 alkyl.


In particular embodiments of the compounds of formula (V), R1 is hydrogen, phenyl (optionally substituted with halogen), or cyclohexyl.


In particular embodiments of the compounds of formula (V), R2 is hydrogen and R3 is selected from the group consisting of:


(1) hydrogen,


(2) aryl (for example, phenyl), or


(3) heteroaryl,


wherein said aryl or heteroaryl R3 moiety is optionally substituted with one or more

    • (a) halo,
    • (b) —C1-6 alkyl, wherein said alkyl is optionally substituted with one or more halogen, and
    • (c) —O—C1-6 alkyl.


In particular embodiments of the compounds of formula (V), R2 is hydrogen and R3 is hydrogen or unsubstituted phenyl.


In other embodiments of the compounds of formula (V), R2 and R3 are linked together to form cyclic group of 4-10 ring carbon atoms, wherein one or two of the ring carbon atoms is replaced by an oxygen, nitrogen or sulfur.


The invention is also directed to methods of treating mammals for diseases in which the β-secretase enzyme is involved, such as Alzheimer's disease, by administering a therapeutically effective amount of a compound of any of the embodiments of formulas (II) to (V).


The invention is also directed to pharmaceutical compositions which include an effective amount of a compound of any of the embodiments of formulas (II) to (V) or pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier.


The invention is further directed to a method for the manufacture of a medicament or a composition for inhibiting β-secretase enzyme activity in humans and animals comprising combining a compound of any of the embodiments of formulas (II) to (V) or a pharmaceutically acceptable salt thereof, with a pharmaceutical carrier or diluent.


In one embodiment, the invention is directed to methods of inhibiting BACE1 enzyme activity, by administering a therapeutically effective amount of a compound of any of the embodiments of formulas (II) to (V).


In another embodiment, the invention is directed to methods of inhibiting BACE2 enzyme activity, by administering a therapeutically effective amount of a compound of any of the embodiments of formulas (II) to (V).


The invention is also directed to a method for the manufacture of a medicament or a composition for treating Alzheimer's Disease in humans, comprising combining a compound of any of the embodiments of formulas (II) to (V) or a pharmaceutically acceptable salt thereof with a pharmaceutical carrier or diluent.


In another embodiment, the invention is directed to compounds of Examples 1—as described herein, or pharmaceutically acceptable salts thereof.


As used herein, the definitions of each of Q-Y—Z should read from left to right, so that when Q is ═CR10—, Y is ═CR10—CR11═ and Z is ═CR10—, the formula (I) ring structure should appear as follows:




embedded image


As used herein, the definitions of X1-X2 are read from left to right, so that when X1-X2 is —CR10R11═CR12CR13—, the formula (I) ring structure should appear as follows:




embedded image


As used herein, the term “alkyl,” by itself or as part of another substituent, means a saturated straight or branched chain hydrocarbon radical having the number of carbon atoms designated (e.g., C1-10 alkyl means an alkyl group having from one to ten carbon atoms). Suitable alkyl groups for use in the invention are C1-6 alkyl groups, having from one to six carbon atoms. Exemplary alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, pentyl, hexyl, and the like.


The term “C0 alkyl,” for example in the term “—C0alkyl-C6-12 aryl”, refers to a bond.


As used herein, the term “alkenyl,” by itself or as part of another substituent, means a straight or branched chain hydrocarbon radical having a single carbon-carbon double bond and the number of carbon atoms designated (e.g., C2-10 alkenyl means an alkenyl group having from two to ten carbon atoms). Suitable alkenyl groups for use in the invention are C2-6 alkenyl groups, having from two to six carbon atoms. Exemplary alkenyl groups include ethenyl and propenyl.


Suitable cycloalkyl groups for use in the invention are monocyclic C3-8 cycloalkyl groups, having from three to eight carbon atoms. Exemplary monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like. Exemplary bridged cycloalkyl groups include adamantly and norbornyl. Exemplary fused cycloalkyl groups include decahydronaphthalene.


As used herein, the term “heterocyclic,” by itself or as part of another substituent, means a cycloalkyl group as defined above, in which one or more of the ring carbon atoms is replaced with a heteroatom (such as N, S or O). Suitable non-aromatic heterocyclic groups for use in the invention include piperidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, tetrahydrofuranyl, pyrrolidinyl, pyrazolidinyl and imidazolidinyl. In certain embodiments, heterocyclic groups for use in the invention have four to eight ring atoms and a single nitrogen or oxygen heteroatom.


When a heterocyclic group as defined herein is substituted, the substituent may be bonded to a ring carbon atom of the heterocyclic group, or to a ring heteroatom (i.e., a nitrogen, oxygen or sulfur), which has a valence which permits substitution. Similarly, when a heterocyclic group is defined as a substituent herein, the point of attachment may be at a ring carbon atom of the heterocyclic group, or on a ring heteroatom (i.e., a nitrogen, oxygen or sulfur), which has a valence which permits attachment.


As used herein, the term “aryl,” by itself or as part of another substituent, means an aromatic or cyclic radical having the number of carbon atoms designated (e.g., C6-10 aryl means an aryl group having from six to ten carbons atoms). The term “aryl” includes multiple ring systems (such as fused ring systems) as well as single ring systems, and includes multiple ring systems wherein part of the molecule is aromatic and part is non-aromatic. A suitable single ring aryl group for use in the invention is phenyl. Suitable fused ring aryl groups include naphthyl, tetrahydronaphthyl and indanyl.


The term “halo” or “halogen” includes fluoro, chloro, bromo and iodo.


As used herein, the term “heteroaryl,” by itself or as part of another substituent, means an aromatic cyclic group having at least one ring heteroatom (O, N or S). The term “heteroaryl” includes multiple ring systems as well as single ring systems. Exemplary heteroaryl groups have from 5 to 12 ring atoms. Exemplary heteroaryl groups include pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, indazolyl, triazinyl, pyranyl, thiazolyl, thienyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzofuranyl, indynyl and benzoxazolyl.


When a heteroaryl group as defined herein is substituted, the substituent may be bonded to a ring carbon atom of the heteroaryl group, or on a ring heteroatom (i.e., a nitrogen, oxygen or sulfur), which has a valence which permits substitution. Similarly, when a heteroaryl group is defined as a substituent herein, the point of attachment may be at a ring carbon atom of the heteroaryl group, or on a ring heteroatom (i.e., a nitrogen, oxygen or sulfur), which has a valence which permits attachment.


As used herein, the term “beta-secretase” or “β-secretase” refers to an enzyme that is sometimes known in the literature as “BACE”, “BACE1” (see, e.g., Vassar et al., 1999, Science 286:735-741), or “BACE2” (see, e.g., Farzan et al., 2000, PNAS 97:9712-9717). BACE1 is a 501 amino acid membrane-bound aspartic protease. BACE1 has all the known functional properties and characteristics of β-secretase. BACE2, also called Asp-1 or memapsin-1, is a second member of the BACE family of membrane-bound aspartic proteases. See Roggo, Current Topics in Medicinal Chemistry, 2002, 2:359-370, for a further discussion of the differences between BACE1 and BACE2.


The compounds of the invention are inhibitors of both the BACE1 and BACE2 enzyme.


The compounds of formula (I) have at least one asymmetric center. Additional asymmetric centers may be present depending upon the nature of the various substituents on the molecule.


Compounds with asymmetric centers give rise to enantiomers (optical isomers), diastereomers (configurational isomers) or both. All of the possible enantiomers and diastereomers in mixtures (as pure or partially purified compounds) are included within the scope of formula (I)


Compounds described herein may contain one or more double bonds, and may thus give rise to cis/trans isomers as well as other configurational isomers. The compounds of formula (I) include all such possible isomers as well as mixtures of such isomers.


Formula (I) is shown above without a definite stereochemistry at certain positions. Figure (I) as depicted includes all stereoisomers of formula (I) and pharmaceutically acceptable salts thereof.


The independent syntheses of the enantiomerically or diastereomerically enriched compounds, or their chromatographic separations, may be achieved as known in the art by appropriate modification of the methodology disclosed herein. Their absolute stereochemistry may be determined by the x-ray crystallography of crystalline products or crystalline intermediates that are derivatized, if necessary, with a reagent containing an asymmetric center of known absolute configuration.


If desired, racemic mixtures of the compounds may be separated so that the individual enantiomers or diastereomers are isolated. The separation can be carried out by methods well known in the art, such as the coupling of a racemic mixture of compounds to an enantiomerically pure compound to form a diastereomeric mixture, followed by separation of the individual diastereomers by standard methods, such as fractional crystallization or chromatography. The coupling reaction is often the formation of salts using an enantiomerically pure acid or base. The diastereomeric derivatives may then be converted to the pure enantiomers by cleavage of the added chiral residue. The racemic mixture of the compounds can also be separated directly by chromatographic methods using chiral stationary phases, which methods are well known in the art.


Alternatively, any enantiomer or diastereomer of a compound may be obtained by stereoselective synthesis using optically pure starting materials or reagents of known configuration by methods well known in the art.


The term “substantially pure” means that the isolated material is at least 90% pure, as assayed by analytical techniques known in the art. In one embodiment, the isolated material is at least 95% pure. In another embodiment, the isolated material is at least 99% pure.


The term “pharmaceutically acceptable salts” refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids including inorganic or organic bases and inorganic or organic acids. The compounds of the invention may be mono, di or tris salts, depending on the number of acid functionalities present in the free base form of the compound. Free bases and salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like. Particular salts are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts in the solid form may exist in more than one crystal structure, and may also be in the form of hydrates. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N′-dibenzylethylene-diamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethyl-morpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like. When the compound of the present invention is basic, salts may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Such acids include acetic, trifluoroacetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid, and the like. Particular salts are the citric, hydrobromic, hydrochloric, trifluoroacetic, maleic, phosphoric, sulfuric, fumaric, and tartaric acids.


The present invention is directed to the use of the compounds of formulas (I) to (III) disclosed herein as inhibitors of β-secretase enzyme activity or β-site amyloid precursor protein-cleaving enzyme (“BACE”) activity, in a patient or subject such as a mammal in need of such inhibition, comprising the administration of an effective amount of the compound. The terms “-secretase enzyme,” “β-site amyloid precursor protein-cleaving enzyme,” and “BACE” are used interchangeably in this specification. In addition to humans, a variety of other mammals can be treated according to the method of the present invention.


The compounds of the present invention have utility in treating, ameliorating, controlling or reducing the risk of Alzheimer's disease. For example, the compounds may be useful for the prevention of dementia of the Alzheimer's type, as well as for the treatment of early stage, intermediate stage or late stage dementia of the Alzheimer's type. The compounds may also be useful in treating, ameliorating, controlling or reducing the risk of diseases mediated by abnormal cleavage of amyloid precursor protein (also referred to as APP), and other conditions that may be treated or prevented by inhibition of β-secretase Such conditions include mild cognitive impairment, Trisomy 21 (Down Syndrome), cerebral amyloid angiopathy, degenerative dementia, Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type (HCHWA-D), Creutzfeld-Jakob disease, prion disorders, amyotrophic lateral sclerosis, progressive supranuclear palsy, head trauma, stroke, pancreatitis, inclusion body myositis, other peripheral amyloidoses, diabetes and atherosclerosis.


The subject or patient to whom the compounds of the present invention is administered is generally a human being, male or female, in whom inhibition of β-secretase enzyme activity is desired, but may also encompass other mammals, such as dogs, cats, mice, rats, cattle, horses, sheep, rabbits, monkeys, chimpanzees or other apes or primates, for which inhibition of β-secretase enzyme activity or treatment of the above noted disorders is desired.


The compounds of the present invention may be used in combination with one or more other drugs in the treatment of diseases or conditions for which the compounds of the present invention have utility, where the combination of the drugs together are safer or more effective than either drug alone. Additionally, the compounds of the present invention may be used in combination with one or more other drugs that treat, prevent, control, ameliorate, or reduce the risk of side effects or toxicity of the compounds of the present invention. Such other drugs may be administered, by a route and in an amount commonly used therefor, contemporaneously or sequentially with the compounds of the present invention. Accordingly, the pharmaceutical compositions of the present invention include those that contain one or more other active ingredients, in addition to the compounds of the present invention. The combinations may be administered as part of a unit dosage form combination product, or as a kit or treatment protocol wherein one or more additional drugs are administered in separate dosage forms as part of a treatment regimen.


The term “composition” as used herein is intended to encompass a product comprising specified ingredients in predetermined amounts or proportions, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts. This term in relation to pharmaceutical compositions is intended to encompass a product comprising one or more active ingredients, and an optional carrier comprising inert ingredients, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients.


Examples of combinations of the compounds of the present invention with other drugs in either unit dose or kit form include combinations with anti-Alzheimer's agents, for example other beta-secretase inhibitors or gamma-secretase inhibitors; glycine transport inhibitors, tau phosphorylation inhibitors; blockers of Aβ oligomer formation; p25/CDK5 inhibitors; HMG-CoA reductase inhibitors; PPAR gamma agonists, such as pioglitazone and rosiglitazone; NK1/NK3 receptor antagonists; NSAID's including ibuprofen; vitamin E; anti-amyloid antibodies, including anti-amyloid humanized monoclonal antibodies; COX-2 inhibitors; anti-inflammatory compounds, such as (R)-flurbiprofen; CB-1 receptor antagonists or CB-1 receptor inverse agonists; antibiotics such as doxycycline and rifampin; N-methyl-D-aspartate (NMDA) receptor antagonists, such as memantine and neramexane; NR2B antagonists; androgen receptor modulators; acetylcholinesterase inhibitors such as galantamine, rivastigmine, donepezil, and tacrine; mGluR5 modulators; growth hormone secretagogues such as ibutamoren, ibutamoren mesylate, and capromorelin; histamine H3 antagonists; AMPA agonists; PDE IV inhibitors; GABAA inverse agonists; GABAA α 5 receptor ligands; GABAB receptor ligands; potassium channel blockers; neuronal nicotinic agonists; P-450 inhibitors, such as ritonavir; or other drugs that affect receptors or enzymes that either increase the efficacy, safety, convenience, or reduce unwanted side effects or toxicity of the compounds of the present invention. The foregoing list of combinations is illustrative only and not intended to be limiting in any way.


In the pharmaceutical composition the active compound, which is a compound of the invention, is included in an amount sufficient to produce the desired effect upon the process or condition of diseases. Accordingly, the pharmaceutical compositions of the present invention encompass any composition made by admixing a compound of the invention and a pharmaceutically acceptable carrier.


The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including intravenous). Thus, the pharmaceutical compositions of the invention can be presented as discrete units suitable for oral administration such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient. Further, the compositions can be presented as a powder, as granules, as a solution, as a suspension in an aqueous liquid, as a non-aqueous liquid, as an oil-in-water emulsion or as a water-in-oil liquid emulsion. In addition to the common dosage forms set out above, the compounds of the invention, may also be administered by controlled release means and/or delivery devices.


Pharmaceutical compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets may contain a compound of the invention in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.


A tablet containing a composition of this invention may be prepared by compression or molding, optionally with one or more accessory ingredients or adjuvants. Compressed tablets may be prepared by compressing, in a suitable machine, a compound of the invention in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent. In certain embodiments, each tablet contains from about 0.1 mg to about 500 mg of the active ingredient and each cachet or capsule contains from about 0.1 mg to about 500 mg of the compound of the invention.


Compositions for oral use may also be presented as hard gelatin capsules wherein the compound of the invention is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the compound of the invention is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.


Other pharmaceutical compositions include aqueous suspensions, which contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. In addition, oily suspensions may be formulated by suspending the compound of the invention in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. Oily suspensions may also contain various excipients. The pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions, which may also contain excipients such as sweetening and flavoring agents.


The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleaginous suspension, or in the form of sterile powders for the extemporaneous preparation of such sterile injectable solutions or dispersions. In all cases, the final injectable form must be sterile and must be effectively fluid for easy syringability. The pharmaceutical compositions must be stable under the conditions of manufacture and storage, and should be preserved against the contaminating action of microorganisms such as bacteria and fungi.


Pharmaceutical compositions of the present invention can be in a form suitable for topical use such as, for example, an aerosol, cream, ointment, lotion, dusting powder, or the like. Further, the compositions can be in a form suitable for use in transdermal devices. These formulations may be prepared via conventional processing methods. As an example, a cream or ointment is prepared by mixing hydrophilic material and water, together with about 5 wt % to about 10 wt % of the compound of the invention, to produce a cream or ointment having a desired consistency.


Pharmaceutical compositions of this invention can also be in a form suitable for rectal administration wherein the carrier is a solid. Suitable carriers include cocoa butter and other materials commonly used in the art.


A “pharmaceutically acceptable excipient,” “pharmaceutically acceptable diluent,” “pharmaceutically acceptable carrier,” and “pharmaceutically acceptable adjuvant” means an excipient, diluent, carrier, and adjuvant that are useful in preparing a pharmaceutical composition that are generally safe, non-toxic and neither biologically nor otherwise-undesirable, and include an excipient, diluent, carrier, and adjuvant that are acceptable for veterinary use as well as human pharmaceutical use. “A pharmaceutically acceptable excipient, diluent, carrier and adjuvant” as used in the specification and claims includes both one and more than one such excipient, diluent, carrier, and adjuvant. By “pharmaceutically acceptable” it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.


Optional” or “optionally” means that the subsequently described event, circumstance, feature, or element may, but need not, occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. For example, “heterocyclo group optionally mono- or di-substituted with an alkyl group” means that the alkyl may, but need not, be present, and the description includes situations where the heterocyclo group is mono- or disubstituted with an alkyl group and situations where the heterocyclo group is not substituted with the alkyl group.


The terms “administration of” or “administering a” compound should be understood to mean providing a compound of the invention to the individual in need of treatment in a form that can be introduced into that individual's body in a therapeutically useful form and therapeutically useful amount, including, but not limited to: oral dosage forms, such as tablets, capsules, syrups, suspensions, and the like; injectable dosage forms, such as IV, IM, or IP, and the like; transdermal dosage forms, including creams, jellies, powders, or patches; buccal dosage forms; inhalation powders, sprays, suspensions, and the like; and rectal suppositories.


The terms “effective amount” or “therapeutically effective amount” means the amount of the subject compound that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician.


As used herein, the term “treatment” or “treating” means any administration of a compound of the invention to obtain a desired pharmacologic and/or physiologic effect. The effect may be prophylactic in terms of completely or partially preventing a disease or symptom thereof, and/or may be therapeutic in terms of a partial or complete cure for a disease and/or adverse affect attributable to the disease. Treatment includes (1) inhibiting the disease in an animal that is experiencing or displaying the pathology or symptomatology of the diseased (i.e., arresting further development of the pathology and/or symptomatology), or (2) ameliorating the disease in an animal that is experiencing or displaying the pathology or symptomatology of the diseased (i.e., reversing the pathology and/or symptomatology).


The terms “individual,” “subject,” and “patient,” used interchangeably herein, refer to a mammal, including, but not limited to, murines, simians, humans, mammalian farm animals, mammalian sport animals, and mammalian pets.


The compositions containing compounds of the invention may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy.


The term “unit dosage form” is taken to mean a single dose wherein all active and inactive ingredients are combined in a suitable system, such that the patient or person administering the drug to the patient can open a single container or package with the entire dose contained therein, and does not have to mix any components together from two or more containers or packages. Typical examples of unit dosage forms are tablets or capsules for oral administration, single dose vials for injection, or suppositories for rectal administration. This list of unit dosage forms is not intended to be limiting in any way, but merely to represent typical examples of unit dosage forms.


Before the present invention is further described, it is to be understood that this invention is not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.


Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges, and are also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.


Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited.


It must be noted that as used herein and in the appended claims, the singular forms “a,” “and,” and “the” include plural referents unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation.


Publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.


The compositions containing compounds of the invention may conveniently be presented as a kit, whereby two or more components, which may be active or inactive ingredients, carriers, diluents, and the like, are provided with instructions for preparation of the actual dosage form by the patient or person administering the drug to the patient. Such kits may be provided with all necessary materials and ingredients contained therein, or they may contain instructions for using or making materials or components that must be obtained independently by the patient or person administering the drug to the patient.


When treating, ameliorating, controlling or reducing the risk of Alzheimer's disease or other diseases for which compounds of the invention are indicated, generally satisfactory results are obtained when the compounds of the invention are administered at a daily dosage of from about 0.1 mg to about 100 mg per kg of animal body weight. For example, the compounds may be given as a single daily dose or in divided doses two to six times a day, or in sustained release form. The total daily dosage is from about 1.0 mg to about 2000 mg (for example, from about 0.1 mg to about 20 mg per kg of body weight). In the case of a 70 kg adult human, the total daily dose will generally be from about 7 mg to about 1,400 mg. This dosage regimen may be adjusted to provide the optimal therapeutic response. The compounds may be administered on a regimen of 1 to 4 times per day, for example once or twice per day.


The amount of the compound of the invention that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. For example, a formulation intended for the oral administration to humans may conveniently contain from about 0.005 mg to about 2.5 g of a compound of the invention, compounded with an appropriate and convenient amount of carrier material. Unit dosage forms will generally contain between from about 0.005 mg to about 1000 mg of the compound of the invention, typically 0.005 mg, 0.01 mg, 0.05 mg, 0.25 mg, 1 mg, 5 mg, 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg or 1000 mg, administered once, twice or three times a day.


It will be understood, however, that the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.


The compounds of the invention may be prepared according to the following reaction Schemes, in which variables are as defined before or are derived, using readily available starting materials, from reagents and conventional synthetic procedures. It is also possible to use variants which are themselves known to those of ordinary skill in organic synthesis art, but are not mentioned in greater detail.


The present invention also provides a method for the synthesis of compounds useful as intermediates in the preparation of compounds of the invention.


Generic scheme I outlines a method for preparing compounds having different combination of 4-spiro fused aryl and amide substituents on the pyrrolidine ring. In this method, the appropriate cyclic ketone A is reacted with triethylphosphonoacetate to yield upon isolation the desired E-stereoisomer B which undergoes dipolar cycloaddition upon treatment with benzyl-N-(methoxymethyl)-trimethylsilylmethyl amine as an azomethine ylide precursor to provide the trans pyrrolidine C. The ester is hydrolyzed and coupled under standard conditions with a suitable amine E. Removal of the benzyl amine by either hydrogenation or other chemical methods such as a-chloroethyl chloroformate yields the target products F.




embedded image


Generic Scheme II outlines a method for preparing 4-spirofused compounds that have a Spiro ring substitution that is not compatible with hydrogenation conditions. In this method, the appropriate ketone is reacted with triethylphosphonoacetate to yield upon isolation the desired E-stereoisomer Bb which undergoes dipolar cycloaddition upon treatment with benzyl-N-(methoxymethyl)-trimethylsilylmethyl amine as an azomethine ylide precursor to provide the trans pyrrolidine Cc. The benzyl protecting group is then exchanged for a t-butoxycarbonyl by sequential treatment with 1-chloroethyl chloroformate, then methanol, and finally BOC anhydride to provide the BOC-protected pyrrolidine Dd. The ester is hydrolyzed and coupled under standard conditions with a suitable amine. TFA mediated deprotection of the t-butyl carbamate yields the desired product Ff.




embedded image


Intermediate I: (2S,4R)-2-cyclohexyl-4-phenylpiperidine



embedded image


Step 1: Benzyl 2-cyclohexyl-4-oxo-3,4-dihydropyridine-1(2H)-carboxylate



embedded image


4-methoxypyridine (17.56 ml, 173 mmol) in THF (577 ml) at −30° C. was added benzyl chloroformate (24.70 ml, 173 mmol) dropwise. Stirred at −30° C. for 30 minutes and then added cyclohexylmagnesium chloride (200 ml, 260 mmol). Stirred for 30 minutes at −30° C. and quenched with 1N HCl. Extracted 3 times with diethyl ether. The combined organic fractions were combined, dried (Na2SO4), filtered and the solvent was evaporated under reduced pressure. Purified on silica gel 30% EtOAc/Hexanes affording 35.25 g.



1H NMR (CDCl3) δ 7.83 (br s, 1H), 7.42-7.36 (m, 5H), 5.34-5.24 (m, 3H), 4.38 (br s, 1H), 2.80-2.72 (m, 1H), 2.66-2.58 (m, 1H), 1.77-1.42 (m, 6H), 1.17-0.91 (m, 5H).


Step 2: Benzyl 2-cyclohexyl-4-oxopiperidine-1-carboxylate



embedded image


Benzyl 2-cyclohexyl-4-oxo-3,4-dihydropyridine-1(2H)-carboxylate (35.25 g, 112 mmol) was dissolved in AcOH (450 ml) and added zinc dust (22.07 g, 337 mmol). The solution stirred at room temperature for 12 hours. The solution was filtered through celite and washed with EtOAc. The solvent was evaporated under reduced pressure and the product was purified by column chromatography on silica gel 30% EtOAc/Hexanes.



1H NMR (CDCl3) δ 7.40-7.31 (m, 5H), 5.22-5.14 (m, 2H), 4.54-4.21 (m, 2H), 3.19-3.08 (m, 1H), 2.62-2.43 (m, 3H), 2.35-2.27 (m, 1H), 1.82-1.53 (m, 6H), 1.42-0.80 (m, 5H).


Step 3: Benzyl 2-cyclohexyl-4-hydroxy-4-phenylpiperidine-1-carboxylate



embedded image


Benzyl 2-cyclohexyl-4-oxopiperidine-1-carboxylate in THF (155 ml) was cooled to 0° C. and added phenylmagnesium bromide (22.08 ml, 61.8 mmol). The ice bath was removed and the solution stirred at room temperature for 14 hours. Quenched the reaction with 1N HCl and concentrated. Extracted three times with EtOAc and washed twice with water. The organics were dried, concentrated, and purified on silica gel 30% EtOAc.



1H NMR (CDCl3) δ 7.47-7.43 (m, 2H), 7.38-7.24 (m, 8H), 5.16 (s, 2H), 4.25-3.92 (m, 2H), 3.40-3.27 (m, 1H), 2.38-2.27 (m, 1H), 2.15-2.04 (m, 1H), 1.92-1.84 (m, 2H), 1.79-1.62 (m, 5H), 1.33-1.08 (m, 4H), 0.98-0.82 (m, 3H).


Step 4: Benzyl 2-cyclohexyl-4-phenyl-3,6-dihydropyridine-1(2H)-carboxylate



embedded image


A solution of BF3OEt2 (4.93 ml, 38.9 mmol) in CH2Cl2 (30 ml) was added to a stirred solution of benzyl 2-cyclohexyl-4-hydroxy-4-phenylpiperidine-1-carboxylate (5 g, 12.71 mmol) in CH2Cl2 (244 ml) at 0° C. The mixture was stirred at room temperature for 15 minutes. Saturated sodium bicarbonate (100 ml) was added after 15 minutes. Extracted twice with CH2Cl2 and the combined organics were dried and concentrated. The crude product was not purified.



1H NMR (CDCl3) δ 7.40-7.22 (m, 10H), 6.21-5.93 (m, 1H), 5.22-5.16 (m, 2H), 4.58-4.10 (m, 2H), 3.74-3.05 (m, 1H), 2.67-2.32 (m, 2H), 1.88-1.55 (m, 6H), 1.27-0.90 (m, 5H).


Step 5: 2-cyclohexyl-4-phenylpiperidine



embedded image


Benzyl 2-cyclohexyl-4-phenyl-3,6-dihydropyridine-1(2H)-carboxylate (4.7 g, 12.52 mmol) in EtOH (25 ml) was added Pd/C (1.18 g, 0.554 mmol) and hydrogenated with a balloon for 10 hours. Filter through celite and concentrate. The crude piperidine was not purified. LRMS (M+H)=217.10


Step 6: Benzyl 2-cyclohexyl-4-phenylpiperidine-1-carboxylate



embedded image


2-cyclohexyl-4-phenylpiperidine (2.85 g, 11.71 mmol) in CH2Cl2 (58.5 ml) was added benzyl chloroformate (2.507 ml, 17.56 mmol) and triethylamine (2.45 ml, 17.56 mmol). The reaction was stirred at room temperature for 2 hours. Added water and extracted 3 times with CH2Cl2. The combined organics were dried, concentrated, and purified on silica gel 20% EtOAc/Hexanes.


Separated cis and trans on the AD column, 20% IPA/Hexanes w/ DEA. Peak 1 corresponds to the cis racemic mixture with one trans diastereomer and peak2 is a single trans diastereomer. Obtained 2.5 g racemic cis/trans peak1. Resolved on the OJ column 20% EtOH/Hexanes w/DEA: Peak 1: 0.68 g pure cis undesired, peak 2 1.75 g cis/trans mixture.



1H NMR (CDCl3) δ 7.39-7.27 (m, 7H), 7.22-7.17 (m, 3H), 5.22-5.14 (m, 2H), 4.04-3.97 (m, 1H), 3.90-3.83 (m, 1H), 3.18-3.09 (m, 1H), 2.72-2.61 (m, 1H), 2.23-2.12 (m, 1H), 1.97-1.90 (m, 1H), 1.74-1.55 (m, 8H), 1.18-0.96 (m, 5H). LRMS (M+H)=378.99


Step 7: (2S,4R)-2-cyclohexyl-4-phenylpiperidine



embedded image


Benzyl 2-cyclohexyl-4-phenylpiperidine-1-carboxylate (1.05 g, 2.78 mmol) in EtOH (50 ml) was added Pd/C (0.5 g, 0.235 mmol) and hydrogenated with a balloon overnight. Filtered through celite and concentrated. The trans isomer was removed on the chiral OD column 20% IPA/Hexanes w/DEA affording the single cis diastereomer.



1H NMR (CDCl3) δ 7.26-7.18 (m, 5H), 3.29-3.23 (m, 1H), 2.82-2.74 (m, 1H), 2.65-2.55 (m, 1H), 2.46-2.39 (m, 1H), 1.93-1.87 (m, 2H), 1.85-1.70 (m, 5H), 1.66-1.53 (m, 2H), 1.38-0.97 (m, 7H).


LRMS (M+H)=244.05


Intermediate II: (2S,4R)-2-(3,3-Difluorocyclohexyl)-4-phenylpiperidine



embedded image


Step 1: 3-Oxocyclohex-1-en-1-yl trifluoromethanesulfonate



embedded image


To a solution of 1 (50 g, 0.48 mmol) and 1,6-lutidine (103 g, 0.96 mmol) in 1 L of dry DCM was added Tf2O (144 ml, 0.72 mmol) dropwise slowly at 0° C. The reaction mixture was stirred at 0° C. for 30 min, warmed to room temperature, stirred for 1 hour, and quenched with HCl (2.0 N). The mixture was partitioned between DCM and diluted aqueous HCl. The organic layer was washed with water and brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. Purification on silica gel afforded 2 as brown liquid (99 g, 85%).


Step 2: 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohex-2-en-1-one



embedded image


To a solution of 2 (55 g, 0.227 mol) and bis-pinacolatodiboron (55.5 g, 0.250 mol) in 600 ml of dry dioxane was added K2CO3 (47 g, 0.341 mol), followed by Pd(PPh3)Cl2 (2.9 g, 6.8 mmol), PPh3 (3.6 g, 13.6 mmol) under nitrogen. The mixture was refluxed for 4 hour, cooled to room temperature, and filtered. The filtrate was used in the next step directly.


Step 3: 3-(4-Phenylpyridin-2-yl)cyclohex-2-en-1-one



embedded image


To a solution 3 (prepared above) in 800 ml of dioxane were added K3PO4 (118 g, 0.561 mol), 2-chloro-4-phenylpyridine (35.5 g, 0.187 mol), and Pd(dppf)Cl2 (6 g, 5.6 mmol). The suspension was stirred at 80° C. overnight, filtered, and concentrated in vacuo. Purification on silica gel afforded 4 as a yellow solid (30 g, 64%).


Step 4: 3-(4-Phenylpyridin-2-yl)cyclohexanone



embedded image


A suspension of 4 (30 g, 0.12 mol) and 2 g of Pd—C in 500 ml of ethyl acetate was hydrogenated under 20 psi of pressure of hydrogen at room temperature overnight. Filtration and concentration afforded crude of 5 as a brown oil (30 g, 100%).


Step 5: 2-(3,3-Difluorocyclohexyl)-4-phenylpyridine



embedded image


To a solution of DAST (213 g, 1.325 mol) in 500 ml of dry DCM was added a solution of 5 (52 g, 0.207 mmol) in 500 ml of DCM at −70° C. After 1 hour, the reaction mixture was warmed to room temperature slowly, and stirred overnight. The reaction was quenched by adding water slowly at 0° C., neutralized with bicarbonate to pH=7˜8, and extracted with DCM. The combined organic layers were washed with water and brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. Purification on silica gel afforded 6 as a yellow liquid (18 g, 32%).


Step 6: 2-(3,3-Difluorocyclohexyl)-1-methyl-4-phenylpyridinium iodide



embedded image


A mixture of 6 (18 g, 66 mmol) and CH3I (105 ml, 198 mmol) in CH3COCH3 (150 ml) in a retort was stirred at 90 degree for 2 days. After cooled to room temperature, the mixture was filtered. The filtered cake was washed with ethyl acetate to give 7 as a yellow solid (23 g, 85%).


Step 7: 2-(3,3-Difluorocyclohexyl)-1-methyl-4-phenylpiperidine



embedded image


The suspension of 7 (1.3 g, 3.1 mmol) and PtO2 (0.26 g) in 50 ml of MeOH was stirred under 1 atmosphere of hydrogen at room temperature overnight, and then filtered. The PtO2 (0.13 g) was added again and the stirring was continued overnight more. After filtered and concentrated, the residue was dissolved in EA and washed with sat. bicarbonate sodium, water, brine, dried over sodium sulfate anhydrous. After filtered and concentrated, 8 (780 mg, 85%) was obtained as a brown oil.


Step 8: 2-(3,3-Difluorocyclohexyl)-4-phenylpiperidine-1-carbonitrile



embedded image


To a solution of 8 (780 mg, 2.7 mmol) in 30 ml of CHCl3 was added K2CO3 (1.3 g, 8.2 mmol) under nitrogen, followed by BrCN (430 mg, 4.1 mmol). The suspension was refluxed overnight. After cooled to room temperature, the reaction mixture was partitioned between DCM and water. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. Purification on silica gel afforded 9 as off-white solid (480 mg, 56%).


Step 9: 2-(3,3-Difluorocyclohexyl)-4-phenylpiperidine



embedded image


The suspension of 9 (480 mg, 1.6 mmol) in 30 ml of diluted aqueous HCl (1N) was refluxed overnight, and concentrated in vacuo. The residue was dissolved in ethyl acetate, washed with saturated aqueous NaHCO3, water, brine, dried over sodium sulfate, filtered, and concentrated in vacuo to give 10 as a colorless oil (400 mg, 91%).


Step 10: Benzyl (2S,4R)-2-(3,3-difluorocyclohexyl)-4-phenylpiperidine-1-carboxylate



embedded image


To a solution of 10 (4.1 g crude, 14.7 mmol) in 100 ml of THF and 50 ml of water was added sodium carbonate (3.9 g, 36.7 mmol), followed by CbzCl (5 g, 29.4 mmol) at room temperature. The reaction mixture was stirred at room temperature overnight, diluted with ethyl acetate, washed with water, brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. Purification on silica gel afforded benzyl 2-(3,3-difluorocyclohexyl)-4-phenylpiperidine-1-carboxylate as a mixture of 4 isomers (2.3 g, 38%). Chiral SFC separation afforded 500 mg of benzyl (2S,4R)-2-(3,3-difluorocyclohexyl)-4-phenylpiperidine-1-carboxylate 11.


Step 11: (2S,4R)-2-(3,3-difluorocyclohexyl)-4-phenylpiperidine



embedded image


A suspension of 11 (500 mg, 1.2 mmol) and Pd(OH)2 (0.2 g) in 10 ml of EtOH was hydrogenated under 1 atmosphere of hydrogen at room temperature overnight. Filtration and concentration afforded (2S,4R)-2-(3,3-difluorocyclohexyl)-4-phenylpiperidine as a colorless oil (330 mg, 98%).


Alternative Procedures for the Preparation of Intermediate II
Step 1: tert-Butyl 2-(3-oxocyclohexyl)-4-phenylpiperidine-1-carboxylate



embedded image


To a solution of compound 1 (10.8 g, 41.2 mmol) in Et2O (150 mL) at −78° C. was added TMEDA (6.2 mL, 41.2 mmol), followed by sec-BuLi (41.4 mL, 1.3 eq, 53.8 mmol). The mixture was stirred at −78° C. for 2 h before a solution of CuCN.2LiCl (3.6 g, 20.6 mmol) in THF (41.2 mL) was added. The reaction mixture was allowed to stir at −50° C. for 1 h before a solution of compound 2 (4 g, 41.2 mmol) in TMSCl (26 mL, 206 mmol) was added. The reaction mixture was stirred at −50° C. for 30 min and then was allowed to stir at room temperature overnight. The reaction mixture was quenched with H2O, stirred at room temperature briefly, diluted with EA, and filtered through Celite. The organic phase was separated, and the aqueous phase was extracted with EA (40 mL×4). The combined organic phases were washed with saturated NH4Cl (aq.), 5% NaHCO3 (aq.), brine, and dried over a mixture of anhydrous Na2SO4 and K2CO3. Evaporation of the solvent in vacuo afforded the crude product which was purified by column chromatography to give 6.8 g of compound 3 in 46% yields.



1H NMR (400 MHz, CDCl3): δ 7.34 (t, J=7.2 Hz, 2H), 7.23 (t, J=7.2 Hz, 3H), 4.31˜4.35 (m, 1H), 4.15˜4.20 (m, 1H), 2.75˜3.0 (m, 2H), 2.25˜2.53 (m, 4H), 1.60˜2.25 (m, 8H), 1.25˜1.59 (m, 10H). LRMS (M+Na+): 380.


Step 2: 3-(4-Phenylpiperidin-2-yl)cyclohexanone



embedded image


To a solution of 3 (6.27 g, 17.6 mmol) in MeOH (20 mL) was added HCl/MeOH (2 M, 40 mL). After 2 hours, the reaction mixture was concentrated to give 5.1 g of compound 4 as HCl salt in 100% yields.


LRMS (M+H+): 258.


Step 3: Benzyl 2-(3-oxocyclohexyl)-4-phenylpiperidine-1-carboxylate



embedded image


To a solution of compound 4 (5.1 g, 17.6 mmol) in DCM (50 mL) were added Et3N (5.3 g, 52.7 mmol) and CbzCl (4.5 g, 26.3 mmol) at 0° C. The mixture was allowed to stir at room temperature for 2 h, and quenched with H2O, extracted with DCM (20 mL×3). The combined organics were washed with brine, dried over Na2SO4 and concentrated. The residue was purified by column chromatography to give 5.56 g of compound 5 in 81% yields.



1H NMR (400 MHz, CDCl3): δ 7.28˜7.39 (m, 7H), 7.15˜7.23 (m, 3H), 5.13˜5.19 (m, 2H), 3.95˜4.45 (m, 2H), 2.60˜3.20 (m, 2H), 1.59˜2.41 (m, 13H). LRMS (M+H+): 392.


Step 4: Benzyl (2S,4R)-2-(3,3-difluorocyclohexyl)-4-phenylpiperidine-1-carboxylate



embedded image


To a solution of compound 5 (5.56 g, 14.2 mmol) in DCM (70 mL) was added dropwise DAST (4 eq, 56.8 mmol) at 0° C. The reaction mixture was stirred at room temperature for 12 h, poured slowly onto ice-water, extracted with DCM (20 mL×3). The combined organics were washed with NaHCO3 (aq.) and brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by p-HPLC to give 3.64 g of benzyl 2-(3,3-difluorocyclohexyl)-4-phenylpiperidine-1-carboxylate in 62% yields as a mixture of 4 isomers.


LRMS (M+H+): 414.


The mixture was resolved by SFC column to give benzyl (2S,4R)-2-(3,3-difluorocyclohexyl)-4-phenylpiperidine-1-carboxylate 6. (Column: Chiralcel OJ-H 250*4.6 mm I.D., 5 um; Mobile phase: methanol (0.05% DEA) in CO2 from 5% to 40%; Flow rate: 2.5 mL/min; Wavelength: 220 nm).


Step 5: (2S,4R)-2-(3,3-difluorocyclohexyl)-4-phenylpiperidine



embedded image


A mixture of compound 6 (130 mg, 0.31 mmol) and Pd (OH)2 (70 mg) in MeOH (20 mL) was stirred at 50° C. under H2 (50 psi) for 4 hours. The mixture was filtrated and the filtrate was concentrated to give 80 mg of (2S,4R)-2-(3,3-difluorocyclohexyl)-4-phenylpiperidine 7 in 92% yields.


LRMS (M+H+): 280.


Intermediate III: 4-phenyl-2-(2,2,2-trifluoroethyl)piperidine



embedded image


Step 1: 2-Chloro-4-phenylpyridine



embedded image


To a mixture of 1 (57.36 g, 0.24 mol) in THF/H2O (400 mL/100 mL) were added phenylboric acid (24.2 g, 0.2 mol) and K2CO3 (82.8 g, 0.6 mol). PdCl2(dppf) (2 g) was then added after being charged with N2 three times. The resulting mixture was refluxed for 2 hrs, cooled, and partitioned between a.q. NH4Cl and EtOAc. The aqueous layer was washed with EtOAc. The combined organic layers were washed with water, brine and dried over Na2SO4. The solvent was removed in vacuo and the residue was purified by silica gel column (PE:EA=10:1) to afford 32 g of 2 (yield 84%).


Step 2: Methyl 4-phenylpyridine-2-carboxylate



embedded image


To a solution of 2 (2 g, 0.01 mol) in MeOH (100 mL) were added TEA (5.33 g, 0.05 mol) and PdCl2(dppf) (0.5 g). The reaction mixture was stirred overnight at 70° C. under 4 MPa CO. The suspension was filtered through a pad of celite and washed with MeOH. The combined filtrates were concentrated in vacuo. Purification on silica gel (PE:EA=10:1) afforded 1.5 g of 3 (yield 71%).



1H-NMR (400 MHz, CDCl3) δ 8.72 (d, 1H), 8.31 (m, 1H), 7.63 (m, 3H), 7.42 (m, 3H), 3.95 (s, 3H)


Step 3: (4-Phenylpyridin-2-yl)methanol



embedded image


To a solution of 3 (1.5 g, 7 mmol) in THF (20 mL) was added LiAlH4 (0.32 g, 8.4 mmol). The reaction mixture was stirred at room temperature for 30 minutes, quenched by adding 15% NaOH aqueous solution, and filtered through silica gel. The filtrate was concentrated to give the crude product, which was used directly in the next step without further purification.


Step 4: 4-Phenylpyridine-2-carbaldehyde



embedded image


To a solution of 4 (1.4 g, 7 mmol) in CH2Cl2 (100 mL) was added MnO2 (1.8 g, 21 mmol). The mixture was refluxed overnight, cooled, and filtered through silica gel. The filtrate was concentrated in vacuo. Purification on silica gel (PE:EA=10:1) afforded 1.1 g of 5 (yield 78%).



1H-NMR (400 MHz, CDCl3) δ 10.14 (s, 1H), 8.82 (d, 1H), 8.18 (m, 1H), 7.64 (m, 3H), 7.45 (m, 3H)


Step 5: 2,2,2-Trifluoro-1-(4-phenylpyridin-2-yl)ethanol



embedded image


To the solution of TMSCF3 (245 mg, 2.5 mmol) in THF (50 mL) were added 5 (366 mg, 2 mmol) and TBAT (cat). The reaction mixture was stirred at room temperature for 1 hr before 1.0 N HCl (5 mL) was added. After 1 hr, the reaction mixture was partitioned between aqueous NaHCO3 and EtOAc. The aqueous layer was washed with EtOAc. The combined organic layers were washed with water and brine, dried over Na2SO4, filtered, and concentrated in vacuo. The crude product thus obtained was used directly in the next step without further purification.



1H-NMR (400 MHz, CDCl3) δ 8.62 (d, 1H), 7.25-7.61 (m, 8H), 5.05 (m, 1H),


Step 6: 4-Phenyl-2-(2,2,2-trifluoroethyl)pyridine



embedded image


A mixture of 6 (647 mg, 2.9 mmol), NaH (232 mg, 5.8 mmol, 60% in mineral oil), imidazole (26 mg, 0.3 mmol) in THF (30 mL) was stirred for a half an hour at room temperature before CS2 (2 mL, 33.3 mmol) was introduced. After stirring for 1 h, iodomethane (0.3 mL, 4.8 mmol) was added. The resultant reaction mixture was stirred for another hour, poured into water (30 mL), extracted with EtOAc two times. The combined organic layers were washed with water and brine, dried over Na2SO4, filtered, and concentrated in vacuo to give a yellow oil. The residue was dissolved in toluene (30 mL), to which catalytic AIBN (100 mg) was added. The reaction mixture was refluxed under N2 while a solution of Bu3SnH (3 mL, 11 mmol) in toluene (3 mL) was added slowly over 30 minutes. After refluxing overnight, the reaction mixture was cooled, partitioned between saturated NaHCO3 aqueous solution and EtOAc. The combined organic layers were washed with water and brine, dried over Na2SO4. The solvent was removed in vacuo and the residue was purified by silica gel column (PE:EA=20:1) to afford 0.32 g of 7 (yield 53%).


Step 7: 4-phenyl-2-(2,2,2-trifluoroethyl)piperidine



embedded image


To a solution of 7 (300 mg, 1.23 mmol) in acetic acid (10 mL) was added Pd/C (100 mg). The reaction mixture was hydrogenated at 80° C. for 2 hrs. LC-MS showed the starting material was consumed. The suspension was filtered through a pad of celite and washed with methanol. The combined filtrates were concentrated in vacuo. The residue was partition between aqueous NaHCO3 and EtOAc. The separated aqueous layer was washed with EtOAc. The combined organic layers were washed with water, brine and dried over Na2SO4. The solvent was removed in vacuo to afford 4-phenyl-2-(2,2,2-trifluoroethyl)piperidine 8.


Intermediate A to YY are depicted below in Table 1. Intermediates A to YY are either commercially available, or are taught in the literature.











TABLE 1





INTER-




MEDIATE
STRUCTURE
SOURCE







A


embedded image


Commercially available





B


embedded image


Commercially available





C


embedded image


Commercially available





D


embedded image


Commercially available





E


embedded image


Commercially available





F


embedded image


Commercially available





G


embedded image


Commercially available





H


embedded image


Commercially available





I


embedded image



Organic Letters (2005), 7(23), 5167-5170






J


embedded image



Synlett (2007), (11), 1699-1702






K


embedded image


Commercially available





L


embedded image


US 2005043309





M


embedded image



J Heterocyclic Chemistry (2000), 37(1), 41-46






N


embedded image


Commercially available





O


embedded image


Commercially available





P


embedded image



Synthesis 1983, 11, 902-903






Q


embedded image



Synthesis 1983, 11, 902-903






R


embedded image


Commercially available





S


embedded image


Commercially available





T


embedded image



J. Med. Chem., 1974, 17(9) 1020-1023






U


embedded image



J. Org. Chem. , (1985), 50(12), 2128-2133






V


embedded image


Commercially available





W


embedded image



Bulletin Chem Soc Japan (1999), 72(2), 303-311






X


embedded image



Chem Communications (2007), 44: 4686-4688






Y


embedded image


Commercially available





Z


embedded image


Commercially available





AA


embedded image



Heterocycles (1986), 24(9); 2011-2618.






BB


embedded image



Indian Journmal of Chem., Section B: Organic Chemistry (1985), 24B(6), 659-661.






CC


embedded image



J. Labelled Compounds andRadiopharmaceuticals (1990), 28(1), 15-24.






DD


embedded image


WO 2005/005438





EE


embedded image



J. Heterocyclic Chem. (1975), 9(1), 44-48.






FF


embedded image



Tetrahedron Letters (1986), 27(10), 1127-1130.






GG


embedded image



Eur. J. Med. Chem. (2000), 39(9), 815-823.






HH


embedded image



J. Org. Chem. (1990), 55(16), 4789-4791.






II


embedded image


U.S. Pat. No. 4,952,694





JJ


embedded image



J. Chem. Soc. Perkin Trans. (1985), (2), 213-219.






KK


embedded image


U.S. Pat. No. 3,998,331





LL


embedded image



Arch. Pharma. (1985), 318(10), 871-878.






MM


embedded image



J. Med Chem. (1977), 20(5), 718-721.






NN


embedded image



J. Heterocyclic Chem., 1983, 649.






OO


embedded image


WO 2006/047017





PP


embedded image



Heterocycles, 1997, 129.






QQ


embedded image



J. Am. Chem. Soc. (1985), 107(17), 4998-4999.






RR


embedded image



J. Am. Chem. Soc. (1985), 107(17), 4998-4999.






SS


embedded image



Heterocycles (1995), 41(1), 29- 36.






TT


embedded image



J. Prak. Chemie (1999), 341(5), 487-491.






UU


embedded image



J. Med. Chem. (1990), 33(11), 3028-3034..






VV


embedded image


Commercially available





WW


embedded image


WO 98/00134





XX


embedded image


Commercially available





YY


embedded image



J. Org. Chem. (2002), 67(11), 3972-3974.










Example 1
4′-[(4-phenylpiperidin-1-yl)carbonyl]-3,4-dihydro-2H-spiro[naphthalene-1,3′-pyrrolidine]



embedded image


Step 1: Ethyl(2E)-3,4-dihydronaphthalen-1(2H)-ylideneacetate



embedded image


Sodium hydride (2.160 g, 54.0 mmol) in THF (150 ml) was added triethyl phosphonoacetate (10.81 ml, 54.0 mmol) dropwise. Stir at room temperature for 1 hour, added α-tetralone (3.99 ml, 30 mmol) and heated overnight at 70° C. The next day the solution was cooled to room temperature and quenched with 1N HCl. Extracted three times with EtOAc and washed the combined organics with brine. The organics were dried over sodium sulfate, concentrated, and purified on silica gel 10% EtOAc/Hex.



1H NMR (CDCl3) δ 7.65 (d, J=7.9 Hz, 1H), 7.27-7.13 (m, 3H), 6.33 (t, J=1.8 Hz, 1H), 4.20 (q, J=7.1 Hz, 2H), 3.22-3.17 (m, 2H), 2.80 (t, J=6.2 Hz, 2H), 1.88-1.83 (m, 2H), 1.32 (t, J=7.1 Hz, 3H). LRMS (M+H)=217.10


Step 2: Ethyl 1′-benzyl-3,4-dihydro-2H-spiro[naphthalene-1,3′-pyrrolidine]-4′-carboxylate



embedded image


N-benzyl-N-(methoxymethyl)-N-trimethylsilylmethylamine (2.112 ml, 8.26 mmol) and ethyl(2E)-3,4-dihydronaphthalen-1(2H)-ylideneacetate (1.785 g, 8.26 mmol) in CH2Cl2 (33.3 ml) at 0° C. was added TFA (0.064 ml, 0.826 mmol) dropwise. Removed the ice bath and stirred at room temperature for 4 hours. Dilute with CH2Cl2 and wash twice with saturated NaHCO3. The organics were dried over sodium sulfate, concentrated, and purified on silica gel 20% EtOAc/Hex.



1H NMR (CDCl3) δ 7.76-7.68 (m, 1H), 7.41-7.18 (m, 6H), 7.15-7.09 (m, 1H), 7.06-6.98 (m, 1H), 4.12-4.03 (m, 2H), 3.75-3.63 (m, 2H), 3.42-3.36 (m, 1H), 3.20-3.10 (m, 1H), 3.07-2.90 (m, 2H), 2.78-2.67 (m, 2H), 2.63-2.57 (m, 1H), 1.89-1.81 (m, 2H), 1.69-1.62 (m, 2H), 1.20-1.09 (m, 3H). LRMS (M+H)=350.20


Step 3: 1′-benzyl-3,4-dihydro-2H-spiro[naphthalene-1,3′-pyrrolidine]-4′-carboxylic acid



embedded image


Ethyl 1′-benzyl-3,4-dihydro-2H-spiro[naphthalene-1,3′-pyrrolidine]-4′-carboxylate (1.1 g, 3.15 mmol) in THF/MeOH/H2O (41 ml) was added 2N sodium hydroxide (4.72 ml, 9.44 mmol). Stir overnight at 50° C. Cooled to room temperature and acidified to pH1-2 with 0.5N HCl and extracted with EtOAc. The organic layer was dried and concentrated. The crude acid was not purified.



1H NMR (CDCl3) δ 7.36-7.22 (m, 6H), 7.11-6.92 (m, 3H), 3.73-3.65 (m, 2H), 3.18-3.11 (m, 2H), 3.00-2.49 (m, 6H), 1.89-1.55 (m, 3H). LRMS (M+H)=322.08


Step 4: N-benzyl-4′-[(4-phenylpiperidin-1-yl)carbonyl]-3,4-dihydro-2H-spiro[naphthalene-1,3′-pyrrolidine]



embedded image


N-benzyl-3,4-dihydro-2H-spiro[naphthalene-1,3′-pyrrolidine]-4′-carboxylic acid (0.1 g, 0.311 mmol) in CH2Cl2 (4 ml) was added oxalyl chloride (0.187 ml, 0.373 mmol) followed by 2 drops of DMF. Stirred at room temperature for 30 minutes and concentrated. Dissolve in THF (5 mL) and added 4-phenylpiperidine (0.050 g, 0.311 mmol) and triethylamine (0.173 ml, 1.245 mmol). The solution was stirred for 2 hours then concentrated, taken up in CH2Cl2 and washed with water. The crude product was not purified.



1H NMR (CDCl3) δ 7.86-7.78 (m, 1H), 7.40-7.35 (m, 2H), 7.31-7.16 (m, 7H), 7.10-7.03 (m, 3H), 7.00-6.95 (m, 1H), 4.88-4.73 (m, 1H), 3.72-3.55 (m, 4H), 3.29-3.08 (m, 5H), 2.76-2.69 (m, 3H), 2.60-2.39 (m, 4H), 2.10-2.02 (m, 1H), 1.80-1.60 (m, 4H). LRMS (M+H)=465.22


Step 5: 4′-[(4-phenylpiperidin-1-yl)carbonyl]-3,4-dihydro-2H-spiro[naphthalene-1,3′-pyrrolidine]



embedded image


N-benzyl-4′-[(4-phenylpiperidin-1-yl)carbonyl]-3,4-dihydro-2H-spiro[naphthalene-1,3′-pyrrolidine] (0.15 g, 0.323 mmol) in EtOH (20 ml) was added Pearlman's Catalyst (0.075 g, 0.107 mmol) and hydrogenated with a balloon for 2 hours. Filtered through celite and concentrated.


The product was purified on the Waters Prep HPLC. The desired fractions were free based with NaHCO3 and extracted 2× with EtOAc.



1H NMR (CD3OD) δ 7.67-7.54 (m, 1H), 7.30-7.08 (m, 6H), 6.96-6.91 (m, 2H), 4.66-4.57 (m, 1H), 4.17-3.98 (m, 2H), 3.72-3.64 (m, 1H), 3.58-3.50 (m, 3H), 2.91-2.73 (m, 3H), 2.65-2.39 (m, 2H), 2.19-2.12 (m, 1H), 2.00-1.60 (m, 5H), 1.53-1.47 (m, 1H), 1.40-1.05 (m, 2H). LRMS (M+H)=375.13


Example 2
[(1R,4′S)-6-methyl-3,4-dihydro-2H-spiro[naphthalene-1,3′-pyrrolidin]-4′-yl](4-phenylpiperidin-1-yl)methanone



embedded image


Step 1: 6-bromo-3,4-dihydronaphthalen-1(2H)-one



embedded image


To a suspension of 6-amino-3,4-dihydro-2H-naphthalen-1-one (20.5 g, 127 mmol) in 25% HBr (aq) (1017 ml) at 0° C. was added a solution of sodium nitrite (10.53 g, 153 mmol) in water (50 ml) dropwise at a rate as to maintain the temperature below 3°. The cooled reaction mixture was then added to a cooled solution of copper(I) bromide (18.79 g, 131 mmol) in HBr (98 ml, 865 mmol). When the addition was done, the reaction mixture was stirred at 0° C. for 1 h, then warmed to rt. Water (380 mL) was added and the product was extracted with a mixture of Et2O/EtOAc (8:2, 3×). The organic layer was dried over Na2SO4, filtered, and concentrated in vacuo to give a dark brown crude oil. The crude was purified by distillation (3 mm Hg) to give 16.415 g of 6-bromo-3,4-dihydro-2H-naphthalen-1-one.



1H NMR (CDCl3): δ 7.89 (d, J=8.6 Hz, 1H); 7.44 (d, J=6.8 Hz, 2H); 2.94 (t, J=6.1 Hz, 2H); 2.65 (t, J=6.5 Hz, 2H); 2.14 (t, J=6.4 Hz, 2H). LRMS (M+H)=226.8


Step 2: Ethyl (2E)-(6-bromo-3,4-dihydronaphthalen-1(2H)-ylidene)ethanoate



embedded image


To a suspension of NaH (2.73 g, 68.4 mmol in THF (190 ml) at room temperature was added triethyl phosphonoacetate (31.3 ml, 157 mmol) dropwise. The resulting solution was stirred at room temperature for 1 h. Then 6-bromo-3,4-dihydronaphthalen-1(2H)-one (19.5839 g, 87 mmol) was added in one portion and the reaction mixture stirred overnight. The reaction mixture was quenched with 1N HCl to pH-1. The mixture was extracted three times with EtOAc. The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give an orange crude oil. The crude was purified on silica gel (8% EtOAc/hexanes) affording 6.7 g of Ethyl (2E)-(6-bromo-3,4-dihydronaphthalen-1(2H)-ylidene)ethanoate.



1H NMR (CDCl3): δ 7.53-7.46 (m, 1H); 7.32 (d, J=6.6 Hz, 2H); 6.30 (s, 1H); 4.20 (q, J=7.1 Hz, 2H); 3.19-3.12 (m, 2H); 2.77 (t, J=6.2 Hz, 2H); 1.84 (p, J=6.3 Hz, 2H); 1.31 (t, J=7.1 Hz, 3H). LRMS (M+H)=296.74


Step 3: Ethyl (1R,4′S)-1′-benzyl-6-bromo-3,4-dihydro-2H-spiro[naphthalene-1,3′-pyrrolidine]-4′-carboxylate



embedded image


To a solution of N-(methoxymethyl)-N-(trimethylsilylmethyl)benzylamine (6.85 ml, 26.8 mmol) and [6-Bromo-3,4-dihydro-2H-naphthalen-(E)-ylidene]-acetic acid ethyl ester (7.9 g, 26.8 mmol) in CH2Cl2 (14.33 ml) at 0° C. was added TFA (0.206 ml, 2.68 mmol) dropwise. The ice bath was removed and the reaction mixture was stirred at room temperature. The process of the reaction was followed by LC/MS. N-(methoxymethyl)-N-(trimethylsilylmethyl)benzylamine (6.85 ml, 26.8 mmol) was added after every 2 h and stirred at room temperature till LC/MS showed no SM. The solution was diluted with CH2Cl2, washed three times with saturated aqueous NaHCO3, dried, filtered, concentrated, and purified on silica gel (10% EtOAc/hexanes) affording 8.85 g of ethyl (1R,4′S)-1′-benzyl-6-bromo-3,4-dihydro-2H-spiro[naphthalene-1,3′-pyrrolidine]-4′-carboxylate.



1H NMR (CDCl3): δ 7.59 (d, J=8.5 Hz, 1H); 7.33-7.22 (m, 5H); 7.22-7.15 (m, 1H); 7.13 (s, 1H); 4.04 (q, J=7.1 Hz, 2H); 3.72-3.58 (m, 2H); 3.33-3.23 (m, 1H); 3.17-3.07 (m, 1H); 2.98-2.88 (m, 1H); 2.86 (d, J=9.2 Hz, 1H); 2.74-2.53 (m, 2H); 2.51 (d, J=9.2 Hz, 1H); 1.81-1.75 (m, 2H); 1.74-1.53 (m, 2H); 1.13 (t, J=7.1 Hz, 3H). LRMS (M±H)=429.72


Step 4: 1′-tert-butyl 4′-ethyl(1R,4′S)-6-bromo-3,4-dihydro-1′H,2H-spiro[naphthalene-1,3′-pyrrolidine]-1′,4′-dicarboxylate



embedded image


To a solution of ethyl (1R,4′S)-1′-benzyl-6-bromo-3,4-dihydro-2H-spiro[naphthalene-1,3′-pyrrolidine]-4′-carboxylate (8.85 g, 20.66 mmol) at 0° C. was added 1-chloroethyl chloroformate (2.68 ml, 24.79 mmol) dropwise. The reaction mixture was stirred at 0° C. for 15 minutes, warmed to room temperature then heated to 40° C. for 2 hours. The reaction was cooled to room temperature concentrated in vacuo. The residue was dissolved in MeOH (275 ml) and heated to reflux for 1 hour. The crude amine was cooled to room temperature, concentrated in vacuo, and reconstituted in THF (207 ml). Boc2O (4.96 g, 22.73 mmol) was added to the solution followed by DIPEA (7.22 ml, 41.3 mmol). The reaction mixture was stirred at room temperature overnight. The solution concentrated, dissolved in CH2Cl2 and washed with water. The organic was dried, filtered, concentrated, and purified on silica gel (15% EtOAc/hexanes) affording 7.1 g of 1′-text-butyl 4′-ethyl(1R,4′S)-6-bromo-3,4-dihydro-1′H,2H-spiro[naphthalene-1,3′-pyrrolidine]-1′,4′-dicarboxylate.



1H NMR (CDCl3): δ 7.31 (dd, J=8.5, 2.1 Hz, 1H); 7.26-7.18 (m, 2H); 4.14-4.05 (m, 2H); 3.95 (ddd, J=15.1, 10.8, 7.1 Hz, 1H); 3.81-3.68 (m, 3H); 3.61 (d, J=11.1 Hz, 1H); 3.47-3.32 (m, 2H); 2.75-2.68 (m, 2H); 1.91-1.77 (m, 2H); 1.76-1.57 (m, 2H); 1.48 (d, J=12.1 Hz, 9H); 1.05 (dt, J=14.7, 7.1 Hz, 3H). LRMS (M+H)=439.74


Step 5: (1R,4′S)-6-bromo-1′-(tert-butoxycarbonyl)-3,4-dihydro-2H-spiro[naphthalene-1,3′-pyrrolidine]-4′-carboxylic acid



embedded image


To a solution of 1′-tert-butyl 4′-ethyl(1R,4′S)-6-bromo-3,4-dihydro-1′H,2H-spiro[naphthalene-1,3′-pyrrolidine]-1′,4′-dicarboxylate (7.1 g, 16.20 mmol) in THF/MeOH/H2O (3:1:1, 40.5 ml) at room temperature was added sodium hydroxide (3M, 16.20 ml, 48.6 mmol) in one portion. The reaction mixture was heated to 55° C. and stirred for 2 hours. The solution was cooled to room temperature, neutralized with 2N HCl, and concentrated to dryness. The residue was diluted with MeOH/chloroform (1:9) and filtered to remove the salt. The filtrate was concentrated to give 6.55 g of crude (1R,4′S)-6-bromo-1′-(tert-butoxycarbonyl)-3,4-dihydro-2H-spiro[naphthalene-1,3′-pyrrolidine]-4′-carboxylic acid. The crude was not purified.



1H NMR (399 MHz, CD3OD): δ 7.42-7.28 (m, 3H); 3.76-3.57 (m, 5H); 2.80-2.74 (m, 3H); 1.93 (s, 1H); 1.79-1.68 (m, 4H); 1.48 (d, J=13.4 Hz, 9H). LRMS (M+H)=411.72


Step 6: tert-butyl (1R,4′S)-6-bromo-4′-[(4-phenylpiperidin-1-yl)carbonyl]-3,4-dihydro-1′H,2H-spiro[naphthalene-1,3′-pyrrolidine]-1′-carboxylate



embedded image


To a solution of (1R,4′S)-6-bromo-1′-(tert-butoxycarbonyl)-3,4-dihydro-2H-spiro[naphthalene-1,3′-pyrrolidine]-4′-carboxylic acid (1.5 g, 3.66 mmol), 4-phenylpiperidine (0.589 g, 3.66 mmol), and BOP (2.425 g, 5.48 mmol) in CH2Cl2 (73 ml) at room temperature was added DIPEA (0.207 ml, 1.187 mmol) in one portion. The reaction mixture was stirred for 15 hours. The solution was diluted with CH2Cl2, washed with water (1×), brine (1×), dried, filtered, concentrated, and purified on silica gel (10%-50% EtOAc/hexanes) affording 1.3 g tert-butyl (1R,4′S)-6-bromo-4′-[(4-phenylpiperidin-1-yl)carbonyl]-3,4-dihydro-1′H,2H-spiro[naphthalene-1,3′-pyrrolidine]-1′-carboxylate.



1H NMR (CDCl3): δ 7.31 (t, J=14.4 Hz, 5H); 7.24-7.16 (m, 1H); 7.12 (s, 1H); 6.98 (d, J=7.2 Hz, 1H); 4.73 (d, J=13.1 Hz, 1H); 4.07 (d, J=10.2 Hz, 1H); 3.71 (d, J=13.9 Hz, 2H); 3.67-3.51 (m, 3H); 2.73 (s, 2H); 2.52 (s, 2H); 1.83 (d, J=13.6 Hz, 1H); 1.72 (s, 4H); 1.47 (d, J=7.8 Hz, 9H); 1.17 (t, J=12.9 Hz, 1H). LRMS (M+H)=554.87


Step 7: [(1R,4′S)-6-methyl-3,4-dihydro-2H-spiro[naphthalene-1,3′-pyrrolidin]-4′-yl](4-phenylpiperidin-1-yl)methanone



embedded image


To a microwave tube equipped with a stir bar was added Pd(Ph3P)4 (94 mg, 0.081 mmol) and potassium carbonate (164 mg, 1.185 mmol). The tube was flushed with argon. Then trimethylboroxine (0.028 ml, 0.203 mmol) was added followed by tert-butyl (1R,4′S)-6-bromo-4′-[(4-phenylpiperidin-1-yl)carbonyl]-3,4-dihydro-1′H,2H-spiro[naphthalene-1,3′-pyrrolidine]-1′-carboxylate (100 mg, 0.181 mmol) in DMF (0.9 ml). The reaction mixture was heated to 105° C. under N2 for 15 hours. The mixture was cooled to room temperature, and filtered through Celite. The wet cake was washed several times with EtOAc. The combined organics were washed once with water and brine, dried, filtered, concentrated. The crude was dissolved in CH2Cl2 (20 ml). QuadraPure TU (1 g) was added and the mixture was stirred at 35° C. for 16 hours. The mixture was filtered through Celite and the wet cake was washed several times with CH2Cl2. The combined organics were concentrated and purified by reverse phase HPLC. The desired fractions were free based with 1N NaOH and extracted three times with CH2Cl2. The residue was dissolved in CH2Cl2. TFA was added and the reaction was stirred at room temperature for 1 hour. The solution was concentrated, basified with 1N NaOH, and extracted three times with CH2Cl2. The combined organics were dried, filtered, and concentrated to give the free amine.



1H NMR (399 MHz, CDCl3): δ 7.36 (d, J=8.1 Hz, 1H); 7.21 (t, J=7.9 Hz, 3H); 7.12 (d, J=7.5 Hz, 1H); 7.04 (d, J=7.2 Hz, 2H); 6.88 (s, 1H); 4.78 (t, J=15.1 Hz, 1H); 3.81 (dd, J=11.7, 5.6 Hz, 1H); 3.67-3.58 (m, 1H); 3.51-3.25 (m, 2H); 3.27-3.13 (m, 1H); 3.05 (d, J=12.0 Hz, 1H); 2.76-2.68 (m, 2H); 2.65-2.49 (m, 4H); 2.26 (d, J=20.3 Hz, 3H); 1.95-1.53 (m, 6H); 1.43 (td, J=12.7, 4.1 Hz, 1H); 1.14 (s, 1H). LRMS (M+H)=388.90


Example 3
[(4R,4′S)-8-methoxy-2,3-dihydrospiro[chromene-4,3′-pyrrolidin]-4′-yl][(2S,4R)-2-(3,3-difluorocyclohexyl)-4-phenylpiperidin-1-yl]methanone



embedded image


Step 1: 1-Methoxy-2-(methoxymethoxy)benzene



embedded image


To a mixture of compound 1 (50 g, 0.4 mol) in DCM (500 mL) were added MOMCl (38.64 g, 0.48 mol) and DIEA (77.4 g, 0.6 mol) at 0° C. The mixture was stirred at room temperature overnight, diluted with EtOAc, and washed with 1N HCl solution. The organic layer were washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. Purification on silica gel (PE:EA=20:1) gave 64 g of compound 2 in 99% yields.



1H NMR CDCl3 (400 MHz, CDCl3): δ 7.12 (d, J=8.0 Hz, 1H), 6.95 (d, J=8.0 Hz, 1H), 6.82 (t, J=8.0 Hz, 2H), 5.21 (s, 2H), 3.86 (s, 3H), 3.5 (s, 3H).


Step 2: 1-Iodo-3-methoxy-2-(methoxymethoxy)benzene



embedded image


To a mixture of compound 2 (48 g, 0.29 mol) in THF (600 mL) was added n-BuLi (197 mL, 1.6 M) at −78° C. After 2 h, a solution of I2 (40 g, 0.16 mol) in THF (200 mL) was added dropwise at −50° C. The reaction mixture was stirred at room temperature overnight, quenched by NH4Cl and Na2S2O5 solutions at 0° C., and extracted with EA. The combined extracts were washed with brine, dried over Na2SO4 and then purified on silica gel (PE:EA=60:1) to give 64 g of compound 3 in 50% yields.



1H NMR (400 MHz, CDCl3): δ 7.28˜7.36 (m, 1H), 7.06˜7.12 (m, 1H), 6.68˜6.76 (m, 1H), 5.16 (s, 2H), 3.82 (s, 3H), 3.46 (s, 3H).


Step 3: 2-Iodo-6-methoxyphenol



embedded image


To a mixture of compound 3 (52 g, 0.18 mol) in MeOH (400 mL) was added HCl/MeOH (100 mL, 2 M) at 0° C. The reaction mixture was stirred at RT for 4 h, then concentrated to give 42 g of compound 4 in 95% yields.



1H NMR (400 MHz, CDCl3): δ 7.12 (d, J=8.0 Hz, 1H), 6.70 (d, J=8.0 Hz, 1H), 6.65 (t, J=8.0 Hz, 1H), 4.46 (s, 1H), 3.75 (s, 3H).


Step 4: 3-(2-Iodo-6-methoxyphenoxy)propan-1-ol



embedded image


A mixture of compound 4 (40 g, 0.16 mol), Br(CH2)3OH (33.3 g, 0.24 mol) and Cs2CO3 (104.3 g, 0.32 mol) in DMF (200 mL) was stirred at room temperature overnight, then diluted with water. The resulting mixture was extracted with EA. The combined extracts were washed with brine, dried over Na2SO4 and then purified on silica gel (PE:EA=30:1) to give 48 g of compound 5 in 60% yields.



1H NMR (400 MHz, CDCl3): δ 7.20˜7.23 (m, 1H), 6.75˜6.78 (m, 1H), 6.68˜6.72 (m, 1H), 3.98˜4.01 (m, 2H), 3.80˜3.83 (m, 2H), 3.40˜3.44 (m, 2H), 1.90˜1.93 (m, 3H).


Step 5: 3-(2-Iodo-6-methoxyphenoxy)propanal



embedded image


To a solution of compound 5 (48 g, 0.16 mol) in DCM (500 mL) at 0° C. were added Py.SO3 (50.9 g, 0.32 mol), DIEA (51.6 g, 0.4 mol) and DMSO (18.72 g, 0.24 mol). The mixture was stirred at 0° C. for 1 h and then quenched by water, extracted with EA. The combined extracts were dried over Na2SO4 and filtered. The filtrate was concentrated to give 48 g of compound 6. It was used directly in the next step without further purification.


Step 6: Ethyl (2E)-5-(2-iodo-6-methoxyphenoxy)pent-2-enoate



embedded image


To a solution of ethyl 2-(diethoxyphosphoryl) acetate (62.7 g, 0.28 mol) in THF (500 mL) at 0° C. was added NaH (6.77 g, 0.28 mol). After stirring for 1 h, a solution of compound 6 (48 g, 0.16 mol) in THF was added dropwise. The mixture was stirred at room temperature overnight, quenched with water, and extracted with EA. The combined extracts were dried over Na2SO4 and filtered. The filtrate was concentrated and purified on silica gel (PE:EA=30:1) to give 13 g of compound 7 in 30% yields.



1H NMR (400 MHz, CDCl3): δ 7.25˜7.28 (m, 1H), 7.03˜7.07 (m, 1H), 6.78˜6.82 (m, 1H), 6.70˜6.75 (m, 1H), 5.9˜5.97 (m, 1H), 4.10˜4.15 (m, 2H), 4.00˜4.05 (m, 2H), 3.75˜3.78 (m, 3H), 2.64˜2.70 (m, 2H), 1.53 (s, 3H). LRMS (M+H+): 377.


Step 7: Ethyl (2E)-(8-methoxy-2,3-dihydro-4H-chromen-4-ylidene)ethanoate



embedded image


A mixture of compound 7 (12 g, 0.032 mol), Ag2CO3 (17.6 g, 0.064 mmol), Pd(AcO)2 (2.5 g, 0.016 mmol) and PPh3 (8.416 g, 0.032 mmol) in toluene (200 mL) was refluxed overnight, filtered, and concentrated in vacuo. Purification on silica gel (PE:EA=30:1) gave 3 g of compound 8 in 39% yields.



1H NMR (400 MHz, CDCl3): δ 7.09˜7.11 (m, 1H), 6.76˜6.82 (m, 1H), 6.28 (s, 1H), 4.22˜4.24 (m, 2H), 4.10˜4.13 (m, 2H), 3.81 (s, 3H), 3.33 (s, 3H), 1.24˜1.26 (m, 3H). LRMS (M+H+): 249.


Step 8: Ethyl (1R,4′S)-8-methoxy-1′-benzyl-2,3-dihydrospiro[chromene-4,3′-pyrrolidine]-4′-carboxylate



embedded image


To a mixture of compound 8 (3 g, 12 mmol) and N-benzyl-N-(methoxymethyl)-N-trimethylsilylmethylamine (8.5 g, 36 mmol) in DCM (5 mL) at 0° C. was added TFA (0.136 g, 1 M in DCM). The mixture was stirred at room temperature overnight, and washed with NaHCO3 solution. The organic layer was dried over Na2SO4, filtered, and concentrated in vacuo. Purification on silica gel (PE:EA=50:1 to 10:1) gave 4.5 g of compound 9 in 99% yields.



1H (400 MHz, CDCl3): δ 7.20˜7.22 (m, 5H), 6.86˜6.88 (m, 1H), 6.70˜6.74 (m, 1H), 6.61˜6.64 (m, 1H), 4.50˜4.53 (m, 2H), 4.00˜4.03 (m, 2H), 3.84 (s, 3H), 3.69 (s, 2H), 3.32 (s, 2H), 2.95 (t, J=12.0 Hz, 2H), 2.61 (d, J=8.0 Hz, 1H), 1.90 (s, 2H), 1.10˜1.14 (m, 3H). LRMS (M+H+): 382


Step 9: 1′-tert-Butyl 4′-ethyl(4R,4′S)-8-methoxy-1′-benzyl-2,3-dihydrospiro[chromene-4,3′-pyrrolidine]-1′,4′-dicarboxylate



embedded image


To a mixture of compound 9 (4.5 g, 11.8 mmol) in EtOH (400 mL) was added Pd/C (450 mg) and Boc2O (10 g, 70.8 mmol). The mixture was stirred at 50° C. under H2 (50 Psi) overnight, and then filtered. The filtrate was purified on silica gel to give 4.5 g of compound 10 in 95% yields.



1H (400 MHz, CDCl3): δ 6.86 (d, J=8.0 Hz, 2H), 6.74 (d, J=8.0 Hz, 1H), 4.10˜4.14 (m, 2H), 3.90˜4.93 (m, 2H), 3.85 (s, 3H), 3.6˜3.64 (m, 2H), 3.4˜3.5 (m, 2H), 2.82˜2.85 (m, 1H), 1.80˜1.85 (m, 2H), 1.43 (s, 9H), 1.00˜1.03 (m, 3H). LRMS (M+H+): 391


Step 10: (1R,4′S)-8-Methoxy-1′-(tert-butoxycarbonyl)-2,3-dihydrospiro[chromene-4,3′-pyrrolidine]-4′-carboxylic acid



embedded image


A mixture of compound 10 (1 g, 2.56 mmol) in NaOH/MeOH (20 mL, 2 M) was stirred at room temperature for 3 h. The mixture was acidified to pH 2˜3 with 2M HCl and extracted to times with CH2Cl2. The combined organic layers were dried over Na2SO4 and concentrated to give 0.85 g of compound 11 in 91% yields.


LRMS (M+H+): 364.


Step 11: [(4R,4′S)-8-methoxy-1′-(tert-butoxycarbonyl)-2,3-dihydrospiro[chromene-4,3′-pyrrolidin]-4′-yl][(2S,4R)-2-(3,3-difluorocyclohexyl)-4-phenylpiperidin-1-yl]methanone



embedded image


A solution of compound 11 (100 mg, 0.275 mmol), (2S,4R)-2-(3,3-difluorocyclohexyl)-4-phenylpiperidine (77 mg, 0.275 mmol), HATU (171 mg, 0.45 mmol) and DIEA (71 mg, 0.6 mmol) in DMF were stirred at room temperature overnight, diluted with EA, and washed with water. The organic layer was dried over Na2SO4, filtered, and concentrated in vacuo. Purification on silica gel gave 70 mg of compound 12 in 41% yields.


LRMS (M+H+): 625.


Step 12: [(4R,4′S)-8-methoxy-2,3-dihydrospiro[chromene-4,3′-pyrrolidin]-4′-yl][(2S,4R)-2-(3,3-difluorocyclohexyl)-4-phenylpiperidin-1-yl]methanone



embedded image


To a solution of compound 12 (70 mg) in 2 mL of MeOH was added a solution of HCl/MeOH (2 mL, 2 M). After 2 h at room temperature, the mixture was concentrated in vacuo to give [(4R,4′S)-8-methoxy-2,3-dihydrospiro[chromene-4,3′-pyrrolidin]-4′-yl][(2S,4R)-2-(3,3-difluorocyclohexyl)-4-phenylpiperidin-1-yl]methanone as HCl salts.


1H NMR (400 MHz, methanol-d4) δ 7.08 (d, J=7.6 Hz, 1H, Ar—H), 6.99 (t, J=7.2 Hz, 2H, Ar—H), 6.89 (d, J=7.2 Hz, 1H, Ar—H), 6.76 (d, J=7.2 Hz, 1H, Ar—H), 6.74 (m, 1H, Ar—H), 6.73 (d, J=8.0 Hz, 1H, Ar—H), 4.08 (m, 3H, CH), 3.77 (m, 2H, CH), 3.58 (m, 2H, CH), 3.45 (s, 3H, OCH3), 3.26 (m, 2H, CH), 2.93 (m, 1H, CH), 2.25 (m, 1H, CH), 1.89 (m, 2H, CH), 1.77 (m, 4H, CH), 1.60 (m, 1H, CH), 1.52 (m, 1H, CH), 1.44 (m, 4H, CH), 1.31 (m, 1H, CH), 0.91 (m, 3H, CH), 0.10 (m, 1H, CH). LRMS (M+H+): 525.


Examples 4-137

The following compounds were prepared similar to Examples 1 and 2 using the starting materials and methods described herein, and applying the knowledge of one of skilled in the art.













TABLE 2









Parent


Ex
Scheme
Product
Name
MW



















4
1


embedded image


(1R,4′S)-2,3- dihydrospiro[indene- 1,3,-pyrrolidin]-4′-yl(4- phenylpiperidin-1- yl)methanone
360.504





5
1


embedded image


(1R,4′S)-2,3- dihydrospiro[indene- 1,3′-pyrrolidin]-4′- yl[(2S,4R)-4-phenyl-2- (propan-2-yl)piperidin- 1-yl]methanone
402.585





6
1


embedded image


(1R,4′S)-3,4-dihydro- 2H-spiro[naphthalene- 1,3′-pyrrolidin]-4′-yl(4- phenylpiperidin-1- yl)methanone
374.531





7
1


embedded image


(1R,4′S)-3,4-dihydro- 2H-spiro[naphthalene- 1,3′-pyrrolidin]-4′- yl[(2S,4R)-4-phenyl-2- (propan-2-yl)piperidin- 1-yl]methanone
416.612





8
1


embedded image


(4R,4′S)-2,3- dihydrospiro[chromene- 4,3′-pyrrolidin]-4′-yl(4- phenylpiperidin-1- yl)methanone
376.503





9
1


embedded image


(1R,4′S)-3,4-dihydro- 2H-spiro[naphthalene- 1,3′-pyrrolidin]-4′- yl[(2S,4R)-2,4- diphenylpiperidin-1- yl]methanone
450.629





10
1


embedded image


(1S,4′S)-3,4-dihydro- 2H-spiro[naphthalene- 1,3′-pyrrolidin]-4′-yl[2- (2-methoxypropan-2- yl)piperidin-1-yl] methanone
370.54





11
1


embedded image


[(1R,4′S)-4,4-dimethyl- 3,4-dihydro-2H-spiro [naphthalene-1,3′- pyrrolidin]-4′-yl](4- phenylpiperidin-1-yl) methanone
402.585





12
1


embedded image


[(2S,4R)-2-cyclohexyl- 4-phenylpiperidin-1- yl][(1R,4′S)-3,4- dihydro-2H-spiro [naphthalene-1,3- pyrrolidin]-4′-yl] methanone
456.677





13
1


embedded image


[(2R,4S)-2-cyclohexyl- 4-phenylpiperidin-1- yl][(1R,4′S)-3,4- dihydro-2H- spiro[naphthalene-1,3′- pyrrolidin]-4′-yl] methanone
456.677





14
2


embedded image


[(1R,4′S)-7-bromo-3,4- dihydro-2H-spiro [naphthalene-1,3- pyrrolidin]-4′-yl](4- phenylpiperidin-1-yl) methanone
453.427





15
1


embedded image


(1S,4′S)-3,4-dihydro- 2H-spiro[naphthalene- 1,3′-pyrrolidin]-4′-yl[2- (3-methoxypentan-3- yl)piperidin-1-yl] methanone
398.594





16
1


embedded image


[(2S,4R)-2-cyclohexyl- 4-phenylpiperidin-1- yl][(1R,4′S)-2,3- dihydrospiro[indene- 1,3′-pyrrolidin]-4′-yl] methanone
442.65





17
2


embedded image


[(1R,4′S)-6-bromo-3,4- dihydro-2H-spiro [naphthalene-1,3′- pyrrolidin]-4′-yl](4- phenylpiperidin-1- yl)methanone
453.427





18
1


embedded image


[(1R,4′S)-6-methoxy- 3,4-dihydro-2H-spiro [naphthalene-1,3- pyrrolidin]-4′-yl](4- phenylpiperidin-1-yl) methanone
404.557





19
2


embedded image


[(1R,4′S)-6-chloro-3,4- dihydro-2H-spiro [naphthalene-1,3′- pyrrolidin]-4′-yl](4- phenylpiperidin-1-yl) methanone
408.976





20
2


embedded image


[(1R,4′S)-6-bromo-3,4- dihydro-2H-spiro [naphthalene-1,3′- pyrrolidin]-4′-yl](1′H- spiro[indene-1,4- piperidin]-1′-yl) methanone
477.449





21
1


embedded image


(1R,4′S)-2,3- dihydrospiro[indene- 1,3′-pyrrolidin]-4′- yl[(2S,4R)-2,4- diphenylpiperidin-1-yl] methanone
436.602





22
2


embedded image


[(1R,4′S)-6-bromo-3,4- dihydro-2H-spiro [naphthalene-1,3- pyrrolidin]-4- yl][(2S,4R)-2,4- diphenylpiperidin-1-yl] methanone
529.525





23
1


embedded image


(1S,4′S)-3,4-dihydro- 2H-spiro[naphthalene- 1,3′-pyrrolidin]-4′-yl(4- phenylpiperidin-1-yl) methanone
374.531





24
1


embedded image


(3R,4S)-2′,3′-dihydro- 1′H-spiro[pyrrolidine- 3,4′-quinolin]-4-yl(4- phenylpiperidin-1-yl) methanone
375.518





25
2


embedded image


[(1R,4′S)-6-bromo-3,4- dihydro-2H-spiro [naphthalene-1,3′- pyrrolidin]-4′-yl] [(2S,4R)-4-phenyl-2- (propan-2-yl)piperidin- 1-yl]methanone
495.508





26
1


embedded image


[(1R,4′S)-6-hydroxy- 3,4-dihydro-2H-spiro [naphthalene-1,3- pyrrolidin]-4′-yl](4- phenylpiperidin-1-yl) methanone
390.53





27
2


embedded image


[(1R,4′S)-5-bromo-3,4- dihydro-2H-spiro [naphthalene-1,3′- pyrrolidin]-4′-yl](4- phenylpiperidin-1-yl) methanone
453.427





28
1


embedded image


[(1R,4′S)-6-fluoro-3,4- dihydro-2H-spiro [naphthalene-1,3- pyrrolidin]-4-yl](4- phenylpiperidin-1-yl) methanone
392.521





29
1


embedded image


(3R,4S)-7′,8′-dihydro- 6′H-spiro[pyrrolidine- 3,5′-quinolin]-4-yl(4- phenylpiperidin-1-yl) methanone
375.518





30
2


embedded image


[(1R,4′S)-5-bromo-2,3- dihydrospiro[indene- 1,3′-pyrrolidin]-4′-yl](4- phenylpiperidin-1-yl) methanone
439.4





31
2


embedded image


(4-phenylpiperidin-1- yl)[(1R,4′S)-5-(propan- 2-yl)-3,4-dihydro-2H- spiro[naphthalene-1,3′- pyrrolidin]-4′-yl] methanone
416.612





32
2


embedded image


[(1R,4′S)-6-bromo-3,4- dihydro-2H-spiro [naphthalene-1,3′- pyrrolidin]-4′-yl] [(2S,4R)-2-cyclohexyl- 4-phenylpiperidin-1-yl] methanone
535.573





33
2


embedded image


[(1R,4′S)-6-bromo-3,4- dihydro-2H-spiro [naphthalene-1,3- pyrrolidin]-4′-y]] [(2R,4S)-2-cyclohexyl- 4-phenylpiperidin-1-yl] methanone
535.573





34
1


embedded image


[(3R,4S)-1′- (methylsulfonyl)-2′,3′- dihydro-1′H-spiro [pyrrolidine-3,4′- quinolin]-4-yl](4- phenylpiperidin-1-yl) methanone
453.608





35
2


embedded image


[(3R,4S)-2,-chloro-7′,8′- dihydro-6′H-spiro [pyrrolidine-3,5- quinolin]-4-yl](4- phenylpiperidin-1-yl) methanone
409.963





36
2


embedded image


[(3R,4S)-2′-chloro-7′,8′- dihydro-6′H-spiro [pyrrolidine-3,5′- quinolin]-4-yl][(2S,4R)- 4-phenyl-2-(propan-2- yl)piperidin-1- yl]methanone
452.045





37
2


embedded image


[(3R,4S)-2′-bromo-7′,8′- dihydro-6′H-spiro [pyrrolidine-3,5′- quinolin]-4-yl](4- phenylpiperidin-1-yl) methanone
454.414





38
1


embedded image


(3R,4S)-2′,3′- dihydrospiro[pyrrolidine- 3,4′-thiochromen]-4- yl(4-phenylpiperidin-1- yl)methanone
392.568





39
2


embedded image


[(3R,4S)-2′- (dimethylamino)-7′,8′- dihydro-6′H-spiro [pyrrolidine-3,5- quinolin]-4-yl](4- phenylpiperidin-1-yl) methanone
418.587





40
2


embedded image


[(3R,4S)-2′- (methylamino)-7′,8′- dihydro-6′H-spiro [pyrrolidine-3,5′- quinolin]-4-yl](4- phenylpiperidin-1-yl) methanone
404.56





41
2


embedded image


[(1R,4′S)-6-ethenyl-3,4- dihydro-2H-spiro [naphthalene-1,3′- pyrrolidin]-4′-yl](4- phenylpiperidin-1-yl) methanone
400.569





42
2


embedded image


[(1R,4′S)-5-amino-2,3- dihydrospiro[indene- 1,3′-pyrrolidin]-4′-yl](4- phenylpiperidin-1-yl) methanone
375.518





43
2


embedded image


[(1R,4′S)-5- (dimethylamino)-2,3- dihydrospiro[indene- 1,3′-pyrrolidin]-4′-yl](4- phenylpiperidin-1-yl) methanone
403.572





44
2


embedded image


[(1R,4′S)-6-ethyl-3,4- dihydro-2H-spiro [naphthalene-1,3′- pyrrolidin]-4′-yl](4- phenylpiperidin-1-yl) methanone
402.585





45
1


embedded image


(4S,4′S)-2,3-dihydro- 1H-spiro[isoquinoline- 4,3′-pyrrolidin]-4′-yl(4- phenylpiperidin-1-yl) methanone
375.518





46
2


embedded image


[(3R,4S)-2′-chloro-7′,8′- dihydro-6′H-spiro [pyrrolidine-3,5′- quinolin]-4-yl](4- phenylpiperidin-1-yl) methanone
409.963





47
1


embedded image


[(3R,4S)-1′,1′-dioxido- 2′,3′-dihydrospiro [pyrrolidine-3,4- thiochromen]-4-yl](4- phenylpiperidin-1-yl) methanone
424.566





48
2


embedded image


[(1R,4′S)-6-methyl-3,4- dihydro-2H-spiro [naphthalene-1,3′- pyrrolidin]-4′-yl](4- phenylpiperidin-1-yl) methanone
388.558





49
2


embedded image


(4-phenylpiperidin-1- yl)[(1R,4′S)-6-(propan- 2-yl)-3,4-dihydro-2H- spiro[naphthalene-1,3′- pyrrolidin]-4′-yl] methanone
416.612





50
2


embedded image


[(3R,4S)-2′-methyl- 7′,8′-dihydro-6′H- spiro[pyrrolidine-3,5- quinolin]-4-yl](4- phenylpiperidin-1-yl) methanone
389.545





51
2


embedded image


[(3R,4S)-21-chloro-7′,8′- dihydro-6′H-spiro [pyrrolidine-3,5- quinolin]-4-yl] [(2R,4S)-2-cyclohexyl- 4-phenylpiperidin-1-yl] methanone
492.11





52
2


embedded image


[(3R,4S)-2′-chloro-7′,8′- dihydro-6′H-spiro [pyrrolidine-3,5- quinolin]-4-yl] [(2S,4R)-2-cyclohexyl- 4-phenylpiperidin-1-yl] methanone
492.11





53
2


embedded image


[(3R,4S)-2′-chloro-7′,8′- dihydro-6′H-spiro [pyrrolidine-3,5- quinolin]-4-yl] [(2R,4R)-2-cyclohexyl- 4-phenylpiperidin-1-yl] methanone
492.11





54
2


embedded image


[(3R,4S)-2′-chloro-7′,8′- dihydro-6′H-spiro [pyrrolidine-3,5′- quinolin]-4-yl][(2S,4S)- 2-cyclohexyl-4- phenylpiperidin-1-yl] methanone
492.11





55
2


embedded image


[(1R,4′S)-6-(morpholin- 4-yl)-3,4-dihydro-2H- spiro[naphthalene-1,3′- pyrrolidin]-4′-yl](4- phenylpiperidin-1-yl) methanone
459.637





56
2


embedded image


[(1R,4′S)-6-tert-butyl- 3,4-dihydro-2H-spiro [naphthalene-1,3′- pyrrolidin]-4′-y1](4- phenylpiperidin-1- yl)methanone
430.639





57
2


embedded image


[(2S,4R)-2-cyclohexyl- 4-phenylpiperidin-1-yl] [(3R,4S)-7′,8′-dihydro- 6′H-spiro[pyrrolidine- 3,5′-quinolin]-4-yl] methanone
457.665





58
2


embedded image


[(1R,4′S)-6- cyclopropyl-3,4- dihydro-2H-spiro [naphthalene-1,3′- pyrrolidin]-4′-yl](4- phenylpiperidin-1- yl)methanone
414.596





59
2


embedded image


(4-phenylpiperidin-1- yl)[(1R,4′S)-6- (trifluoromethyl)-3,4- dihydro-2H-spiro [naphthalene-1,3′- pyrrolidin]-4′-yl] methanone
442.529





60
2


embedded image


[(3R,4S)-2′-chloro-7′,8′- dihydro-6′H-spiro [pyrrolidine-3,5′- quinolin]-4-yl] [(2S,4R)-2,4- diphenylpiperidin-1- yl]methanone
486.062





61
2


embedded image


[(2S,4R)-2,4- diphenylpiperidin-1- yl][(3R,4S)-2′-methyl- 7′,8′-dihydro-6′H-spiro [pyrrolidine-3,5- quinolin]-4-yl] methanone
465.644





62
2


embedded image


[(3R,4S)-2′-bromo-7′,8′- dihydro-6′H-spiro [pyrrolidine-3,5 - quinolin]-4-yl] [(2S,4R)-2-cyclohexyl- 4-phenylpiperidin-1-yl] methanone
536.561





63
2


embedded image


[(2S,4R)-2-cyclohexyl- 4-phenylpiperidin-1- yl][(3R,4S)-2′-methyl- 7′,8′-dihydro-6′H-spiro [pyrrolidine-3,5′- quinolin]-4-yl] methanone
471.692





64
2


embedded image


[(1R,4′S)-6- (difluoromethyl)-3,4- dihydro-2H-spiro [naphthalene-1,3- pyrrolidin]-4-yl](4- phenylpiperidin-1-yl) methanone
424.539





65
2


embedded image


[(1R,4′S)-6- (hydroxymethyl)-3,4- dihydro-2H-spiro [naphthalene-1,3′- pyrrolidin]-4′-yl](4- phenylpiperidin-1-yl) methanone
404.557





66
2


embedded image


[(1R,4′S)-6- (aminomethyl)-3,4- dihydro-2H-spiro [naphthalene-1,3′- pyrrolidin]-4′-yl](4- phenylpiperidin-1-yl) methanone
403.572





67
2


embedded image


[(1R,4′S)-6- (fluoromethyl)-3,4- dihydro-2H-spiro [naphthalene-1,3′- pyrrolidin]-4′-yl](4- phenylpiperidin-1-yl) methanone
406.548





68
1


embedded image


[(2S,4R)-2-cyclohexyl- 4-phenylpiperidin-1- yl][(4S,4′S)-2,3- dihydro-1H-spiro [isoquinoline-4,3- pyrrolidin]-4′-yl] methanone
457.665





69
1


embedded image


[(2S,4R)-2-cyclohexyl- 4-phenylpiperidin-1- yl][(4R,4,R)-2,3- dihydro-1H-spiro [isoquinoline-4,3- pyrrolidin]-4′-yl] methanone
457.665





70
2


embedded image


[(2S,4R)-2-cyclohexyl- 4-phenylpiperidin-1-yl] [(3R,4S)-2′-(propan-2- yl)-7′,8′-dihydro-6′H- spiro[pyrrolidine-3,5′- quinolin]-4-yl] methanone
499.746





71
2


embedded image


(4-phenylpiperidin-1- yl)[(1R,4′S)-6-(2,2,2- trifluoro-1- hydroxyethyl)-3,4- dihydro-2H-spiro [naphthalene-1,3′- pyrrolidin]-4′-yl] methanone
472.556





72
2


embedded image


[(3R,4S)-2′-methyl- 7′,8′-dihydro-6′H- spiro[pyrrolidine-3,5- quinolin]-4-yl] [(2S,4R)-4-phenyl-2- (propan-2-yl)piperidin- 1-yl]methanone
431.627





73
2


embedded image


[(2S,4R)-2-cyclohexyl- 4-phenylpiperidin-1- yl][(3R,4S)-1′-oxido- 7′,8′-dihydro-6′H-spiro [pyrrolidine-3,5′- quinolin]-4-yl] methanone
473.664





74
2


embedded image


[(2S,4R)-2-tert-butyl-4- phenylpiperidin-1-yl] [(3R,4S)-2′-methyl- 7′,8′-dihydro-6′H-spiro [pyrrolidine-3,5′- quinolin]-4-yl] methanone
445.654





75
1


embedded image


(4-phenylpiperidin-l-yl) [(4S,4′S)-1H- spiro[isochromene-4,3′- pyrrolidin]-4′-yl] methanone
376.503





76
2


embedded image


[(3R,4S)-2′-chloro-7′,8′- dihydro-6′H-spiro [pyrrolidine-3,5- quinolin]-4-yl] [(2S,4R)-2-(pentan-3- yl)-4-phenylpiperidin-1- yl]methanone
480.099





77
2


embedded image


[(3R,4S)-2′-chloro-7′,8′- dihydro-6′H-spiro [pyrrolidine-3,5′- quinolin]-4-yl](2′- phenyl-1′H-spiro [indene-1,4′-piperidin]- 1′-yl)methanone
510.084





78
2


embedded image


[(3R,4S)-2′-methyl- 7′,8′-dihydro-6′H- spiro[pyrrolidine-3,5′- quinolin]-4-yl] [(2S,4R)-2-(pentan-3- yl)-4-phenylpiperidin-1- yl]methanone
459.681





79
2


embedded image


[(2S,4R)-2-cyclohexyl- 4-phenylpiperidin-1-yl] [(1R,4′S)-6- (hydroxymethyl)-3,4- dihydro-2H-spiro [naphthalene- 1,3′- pyrrolidin]-4′-yl] methanone
486.70





80
2


embedded image


[(4S)-2′-chloro-7′,8′- dihydro-6′H-spiro [pyrrolidine-3,5′- quinolin]-4-yl](4- phenyl-2- propylpiperidin-1-yl) methanone
453.052





81
2


embedded image


[(4S)-2′-chloro-7′,8′- dihydro-6′H-spiro [pyrrolidine-3,5- quinolin]-4-yl][2-(2- methylpropyl)-4- phenylpiperidin-1-yl] methanone
466.072





82
2


embedded image


[(4S)-2′-chloro-7′,8′- dihydro-6′H-spiro [pyrrolidine-3,5′- quinolin]-4-yl](4- phenyl-2- propylpiperidin-1- yl)methanone
466.072





83
2


embedded image


[(4S)-2′-chloro-7′,8′- dihydro-6′H-spiro [pyrrolidine-3,5- quinolin]-4-yl][2-(4- fluorophenyl)-4- phenylpiperidin-1-yl] methanone
504.052





84
1


embedded image


2,3-dihydrospiro [chromene-4,3′- pyrrolidin]-4′-yl(2,4- diphenylpiperidin-1-yl) methanone
452.602





85
2


embedded image


(6-bromo-2,3- dihydrospiro[indene- 1,3′-pyrrolidin]-4′-yl)[2- (4-fluorophenyl)-4- phenylpiperidin-1-yl] methanone
533.489





86
2


embedded image


[(3R,4S)-2′-chloro-7′,8′- dihydro-6′H-spiro [pyrrolidine-3,5′- quinolin]-4-yl](4- phenyl-2-propylazepan- 1-yl)methanone
466.072





87
2


embedded image


(6-bromo-2,3- dihydrospiro[indene- 1,3′-pyrrolidin]-4′- yl)(2,4- diphenylpiperidin-1-yl) methanone
515.498





88
2


embedded image


(2′-chloro-7′,8′-dihydro- 6′H-spiro[pyrrolidine- 3,5′-quinolin]-4-yl)(2,4- diphenylpiperidin-1-yl) methanone
486.062





89
1


embedded image


2,3-dihydrospiro [chromene-4,3′- pyrrolidin]-4′-yl[4- phenyl-2-(prop-2-en-1- yl)piperidin-l-yl] methanone
416.568





90
1


embedded image


2,3-dihydrospiro [chromene-4,3′- pyrrolidin]-4′-yl[2-(2- fluorophenyl)-4- phenylpiperidin-1-yl] methanone
470.592





91
1


embedded image


2,3-dihydrospiro [chromene-4,3′- pyrrolidin]-4′-yl[2-(4- fluorophenyl)-4- phenylpiperidin-1-yl] methanone
470.592





92
2


embedded image


(2,4-diphenylpiperidin- 1-yl)(6-ethyl-2,3- dihydrospiro[indene- 1,3′-pyrrolidin]-4′-yl) methanone
464.657





93
2


embedded image


(3-benzylpiperidin-1- yl)[(3R,4S)-2′-chloro- 7′,8′-dihydro-6′H- spiro[pyrrolidine-3,5′- quinolin]-4-yl] methanone
423.99





94
2


embedded image


[(3R,4S)-2′-chloro-7′,8′- dihydro-6′H-spiro [pyrrolidine-3,5′- quinolin]-4-yl](1′H- spiro[1-benzofuran-3,4′- piperidin]-1′-yl) methanone
437.974





95
2


embedded image


[(3R,4S)-2′-chloro-7′,8′- dihydro-6′H-spiro [pyrrolidine-3,5′- quinolin]-4-yl](1,2- dihydro-1′H-spiro [indole-3,4′-piperidin]- 1′-yl)methanone
436.989





96
1


embedded image


(2-butyl-2,3- dihydrospiro[chromene- 4,3′-pyrrolidinl-4′- yl)(2,4- diphenylpiperidin-1- yl)methanone
508.71





97
2


embedded image


(2′-chloro-7′,8′-dihydro- 6′H-spiro[pyrrolidine- 3,5′-quinolin]-4-yl)(5- phenyl-2-propylazepan- 1-yl)methanone
466.072





98
2


embedded image


(2′-chloro-7′,8′-dihydro- 6′H-spiro[pyrrolidine- 3,5′-quinolin]-4-yl)[4- phenyl-2-(prop-2-en-1- yl)piperidin-1-yl] methanone
450.029





99
2


embedded image


(2′-chloro-7′,8′-dihydro- 6′H-spiro[pyrrolidine- 3,5′-quinolin]-4-yl)[2- (2-fluorophenyl)-4- phenylpiperidin-1-yl] methanone
504.052





100
2


embedded image


[(3R,4S)-2′-chloro-7′,8′- dihydro-6′H-spiro [pyrrolidine-3,5′- quinolin]-4-yl][2-(3- methylphenyl)-4- phenylpiperidin-1-yl] methanone
500.089





101
1


embedded image


(4R,4′S)-2,3- dihydrospiro[chromene- 4,3′-pyrrolidin]-4′- yl[(2S,4R)-2,4- diphenylpiperidin-1-yl] methanone
452.602





102
1


embedded image


[(2S,4R)-2,4- diphenylpiperidin-1- yl][(4R,4′S)-2-methyl- 2,3-dihydrospiro [chromene-4,3′- pyrrolidin]-4′-yl] methanone
466.629





103
1


embedded image


[(4R,4′S)-2-butyl-2,3- dihydrospiro[chromene- 4,3′-pyrrolidin]-4′-yl] [(2S,4R)-2,4- diphenylpiperidin-1-yl] methanone
508.71





104
2


embedded image


[(4R,4′S)-6-chloro-2,3- dihydrospiro[chromene- 4,3′-pyrrolidin]-4′-yl] [(2S,4R)-2,4- diphenylpiperidin-1-yl] methanone
487.047





105
2


embedded image


[(4R,4′S)-6-chloro-7- methyl-2,3- dihydrospiro[chromene- 4,3′-pyrrolidin]-4′-yl] [(2S,4R)-2,4- diphenylpiperidin-1-yl] methanone
501.074





106
2


embedded image


[(3R,4S)-2′-chloro-1′- oxido-7′,8′-dihydro-6′H- spiro[pyrrolidine-3,5- quinolin]-4-yl] [(2R,4S)-2,4- diphenylpiperidin-1-yl] methanone
502.061





107
2


embedded image


[(2R,4S)-2,4- diphenylpiperidin-1- yl][(3R,4S)-2′-ethyl- 7′,8′-dihydro-6′H- spiro[pyrrolidine-3,5- quinolin]-4-yl] methanone
479.671





108
2


embedded image


[(3R,4S)-2′-chloro-7′,8′- dihydro-6′H-spiro [pyrrolidinc-3,5- quinolin]-4-yl][2′-(4- fluorophenyl)-1′H- spiro[indene-1,4′- piperidin]-1′-yl] methanone
528.075





109
2


embedded image


[(3R,4S)-2′-chloro-7′,8′- dihydro-6′H-spiro [pyrrolidine-3,5′- quinolin]-4-yl](2′- phenyl-1′H-spiro [indene-1,4′-piperidin]- 1′-yl)methanone
510.084





110
1


embedded image


(4R,4′S)-4′-{[(2S,4R)- 2,4-diphenylpiperidin-1- yl]carbonyl}-1,5,6,7- tetrahydrospiro[indole- 4,3′-pyrrolidine]
439.59





111
1


embedded image


(4R,4′S)-4'-{[(2S,4R)- 2,4-diphenylpiperidin-1- yl]carbonyl}-6,7- dihydro-5H-spiro[1- benzothiophene-4,3′- pyrrolidine]
456.64





112
1


embedded image


(4R,4′S)-4′-{[(2S,4R)- 2,4-diphenylpiperidin-1- yl]carbonyl}-6,7- dihydro-5H-spiro[1- benzofuran-4,3′- pyrrolidine]
440.58





113
1


embedded image


(4′S,7S)-4′-{[(2S,4R)- 2,4-diphenylpiperidin-1- yl]carbonyl}-2-methyl- 5,6-dihydro-4H- spiro[1,3-benzothiazole- 7,3′-pyrrolidine]
471.66





114
1


embedded image


(4′S,7S)-4′-{[(2S,4R)- 2,4-diphenylpiperidin-1- yl]carbonyl}-5,6- dihydro-4H-spiro[1- benzothiophene-7,3′- pyrrolidine]
456.64





115
1


embedded image


(4′S,7S)-4′-{[(2S,4R)- 2,4-diphenylpiperidin-1- yl]carbonyl}-5,6- dihydro-4H-spiro[1- benzofuran-7,3′- pyrrolidine]
440.58





116
1


embedded image


(3R,4S)-4-{[(2S,4R)- 2,4-diphenylpiperidin-1- yl]carbonyl}-7′-methyl- 2′,3′- dihydrospiro[pyrrolidine- 3,4′-thiopyrano[2,3-b] pyridine]
483.67





117
2


embedded image


(3S,4S)-2′-chloro-4- {[(2S,4R)-2,4- diphenylpiperidin-1- yl]carbonyl}-6′,7′- dihydro-5′H-spiro [pyrrolidine-3,8′- quinoline]
486.05





118
2


embedded image


(3R,4S)-3′-chloro-4- {[(2S,4R)-2,4- diphenylpiperidin-1- yl]carbonyl}-7′,8′- dihydro-6′H-spiro [pyrrolidine-3,5- quinoline]
486.05





119
1


embedded image


(3S,4S)-4-{[(2S,4R)- 2,4-diphenylpiperidin-1- yl]carbonyl}-2′-phenyl- 6′,7′-dihydro-5′H- spiro[pyrrolidine-3,8′- quinoline]
527.7





120
1


embedded image


(3R,4S)-4-{[(2S,4R)- 2,4-diphenylpiperidin-1- yl]carbonyl}-3′-methyl- 7′,8′-dihydro-6′H- spiro[pyrrolidine-3,5′- quinoline]
464.64





121
1


embedded image


(3R,4S)-4-{[(2S,4R)- 2,4-diphenylpiperidin-1- yl]carbonyl}-4-methyl- 7′,8′-dihydro-6′H- spiro[pyrrolidine-3,5′- quinoline]
464.64





122
1


embedded image


(3S,4S)-4-{[(2S,4R)- 2,4-diphenylpiperidin-1- yl]carbonyl}-3-methyl- 6′,7′-dihydro-5′H- spiro[pyrrolidine-3,8′- quinoline]
464.64





123
1


embedded image


(3R,4S)-4-{[(2S,4R)- 2,4-diphenylpiperidin-1- yl]carbonyl}-2′-methyl- 7′,8′-dihydro-6′H- spiro[pyrrolidine-3,5′- quinazoline]
465.63





124
1


embedded image


(3R,4S)-4-{[(2S,4R)- 2,4-diphenylpiperidin-1- yl]carbonyl}-2-phenyl- 7′,8′-dihydro-6′H- spiro[pyrrolidine-3,5- quinazoline]
527.7





125
1


embedded image


(3S,4S)-4-{[(2S,4R)- 2,4-diphenylpiperidin-1- yl]carbonyl}-7′,8′- dihydro-6′H-spiro [pyrrolidine-3,5′- quinoxaline]
451.6





126
1


embedded image


(3R,4S)-4-{[(2S,4R)- 2,4-diphenylpiperidin-1- yl]carbonyl}-4′- (trifluoromethyl)-7′,8′- dihydro-6′H-spiro [pyrrolidine-3,5′- quinoline]
518.61





127
1


embedded image


(4′S,8R)-4′-{[(2S,4R)- 2,4-diphenylpiperidin-1- yl]carbonyl}-1,3- dimethyl-6,7-dihydro- 5H-spiro[isoquinoline- 8,3′-pyrrolidine]
478.67





128
1


embedded image


(1R,4′S)-4′-{[(2S,4R)- 2,4-diphenylpiperidin-1- yl]carbonyl}-6,8- dimethyl-3,4-dihydro- 2H-spiro[naphthalene- 1,3′-pyrrolidine]
478.67





129
1


embedded image


(1R,4′S)-4′-{[(2S,4R)- 2,4-diphenylpiperidin-1- yl]carbonyl}- 3,4,5,6,7,8-hexahydro- 2H-spiro[acridine-1,3′- pyrrolidine]
504.7





130
1


embedded image


(4′S,9R)-4′-{[(2S,4R)- 2,4-diphenylpiperidin-1- yl]carbonyl}- 1,2,3,6,7,8- hexahydrospiro [cyclopenta[c]quinoline- 9,3′-pyrrolidine]
520.75





131
1


embedded image


(4R,4′S)-4′-{[(2S,4R)- 2,4-diphenylpiperidin-1- yl]carbonyl}-2,2- dimethyl-2,3- dihydrospiro[chromene- 4,3′-pyrrolidine]
479.65





132
2


embedded image


(4R,4′S)-7-bromo-4′- {[(2S,4R)-2,4- diphenylpiperidin-1- yl]carbonyl}-2,3- dihydrospiro[chromene- 4,3′-pyrrolidine]
530.5





133
2


embedded image


(3S,4′S)-6-bromo-4′- {[(2S,4R)-2,4- diphenylpiperidin-1- yl]carbonyl}spiro[1- benzofuran-3,3′- pyrrolidine]
516.47





134
2


embedded image


(1R,4′S)-5-bromo-4′- {[(2S,4R)-2,4- diphenylpiperidin-1- yl]carbonyl}-2,3- dihydrospiro[indene- 1,3′-pyrrolidine]
514.5





135
1


embedded image


(1S,4′S)-7-bromo-4′- {[(2S,4R)-2,4- diphenylpiperidin-1- yl]carbonyl}-4,5- dihydrospiro[3- benzoxepine-1,3′- pyrrolidine]
465.63









Compounds in Table 2 having a basic group or acidic group are depicted and named as the free base acid. Depending on the reaction and purification conditions, various compounds in Table 1 having a basic group were isolated in either the free base form, or as a salt (such as HCl salt), or in both free base and salt forms.


The following compounds were prepared similar to Examples 1 to 3 using the starting materials and methods described herein, and applying the knowledge of one of skilled in the art.















Ex.


Parent


No.
Scheme
Structure
MW


















136
2


embedded image


462.594





137
2


embedded image


532.68





138
2


embedded image


534.696





139
2


embedded image


478.705





140
2


embedded image


522.685





141
2


embedded image


470.564





142
2


embedded image


448.611





143
2


embedded image


556.674





144
2


embedded image


487.57





145
2


embedded image


514.686





146
2


embedded image


524.657





147
2


embedded image


556.553





148
2


embedded image


498.715





149
2


embedded image


537.546





150
2


embedded image


507.673





151
2


embedded image


484.668





152
2


embedded image


486.704





153
2


embedded image


471.677





154
2


embedded image


496.699





155
2


embedded image


478.554





156
2


embedded image


555.569





157
2


embedded image


506.666





158
2


embedded image


576.646





159
2


embedded image


488.555





160
2


embedded image


472.558





161
2


embedded image


471.571





162
2


embedded image


476.649





163
2


embedded image


514.714





164
2


embedded image


537.546





165
2


embedded image


533.736





166
2


embedded image


525.663





167
2


embedded image


501.554





168
2


embedded image


452.574





169
2


embedded image


462.638





170
2


embedded image


489.664





171
2


embedded image


573.68





172
2


embedded image


502.66





173
2


embedded image


537.656





174
2


embedded image


522.685





175
2


embedded image


524.657





176
2


embedded image


476.665





177
2


embedded image


542.647





178
2


embedded image


445.595





179
2


embedded image


488.592





180
2


embedded image


473.708





181
2


embedded image


498.715





182
2


embedded image


491.655





183
2


embedded image


524.657





184
2


embedded image


488.676





185
2


embedded image


502.703





186
2


embedded image


450.583





187
2


embedded image


446.595





188
2


embedded image


610.646





189
2


embedded image


474.693





190
2


embedded image


592.655





191
2


embedded image


544.663





192
2


embedded image


570.673





193
2


embedded image


488.555





194
2


embedded image


501.675





195
2


embedded image


420.557





196
2


embedded image


542.647





197
2


embedded image


420.557





198
2


embedded image


507.673





199
2


embedded image


532.677





200
2


embedded image


525.663





201
2


embedded image


507.673





202
2


embedded image


434.584





203
2


embedded image


522.685





204
2


embedded image


476.665





205
2


embedded image


521.149





206
2


embedded image


556.674





207
2


embedded image


591.671





208
2


embedded image


543.679





209
2


embedded image


542.74





210
2


embedded image


505.682





211
2


embedded image


526.651





212
2


embedded image


508.66





213
2


embedded image


560.731





214
2


embedded image


509.763





215
2


embedded image


497.752





216
2


embedded image


481.709





217
2


embedded image


545.709





218
2


embedded image


559.736





219
2


embedded image


471.692





220
2


embedded image


500.734





221
2


embedded image


397.481





222
2


embedded image


413.543





223
2


embedded image


412.493





224
2


embedded image


466.072





225
2


embedded image


536.561





226
2


embedded image


465.644





227
2


embedded image


479.671





228
2


embedded image


524.55





229
2


embedded image


459.681





230
2


embedded image


406.529





231
2


embedded image


609.661





232
2


embedded image


525.663





233
2


embedded image


507.673





234
2


embedded image


501.675





235
2


embedded image


431.539





236
2


embedded image


524.657





237
2


embedded image


446.595





238
2


embedded image


448.611





239
2


embedded image


471.692





240
2


embedded image


464.056





241
2


embedded image


452.045





242
2


embedded image


473.664





243
2


embedded image


486.583





244
2


embedded image


450.029





245
2


embedded image


488.676





246
2


embedded image


555.69





247
2


embedded image


503.709





248
2


embedded image


510.1





249
2


embedded image


510.1





250
2


embedded image


494.748





251
2


embedded image


506.71





252
2


embedded image


482.628





253
2


embedded image


466.629





254
2


embedded image


488.676





255
2


embedded image


553.773





256
2


embedded image


539.746





257
2


embedded image


545.149





258
2


embedded image


565.784





259
2


embedded image


551.757





260
2


embedded image


530.513





261
2


embedded image


480.656





262
2


embedded image


476.665





264
2


embedded image


452.602





265
2


embedded image


502.703





266
2


embedded image


503.709





267
2


embedded image


485.719





268
2


embedded image


459.681





269
2


embedded image


459.681





270
2


embedded image


501.718





271
2


embedded image


522.136





272
2


embedded image


512.701





273
2


embedded image


502.703





274
2


embedded image


541.663





275
2


embedded image


493.097





276
2


embedded image


498.089





277
2


embedded image


481.086





278
2


embedded image


518.721





279
2


embedded image


502.706





280
2


embedded image


514.714





281
2


embedded image


555.69





282
2


embedded image


555.69





283
2


embedded image


471.692





284
2


embedded image


566.587





285
2


embedded image


488.679





286
2


embedded image


499.746





287
2


embedded image


505.682





288
2


embedded image


486.704





289
2


embedded image


474.693





290
2


embedded image


531.498





291
2


embedded image


554.702





292
2


embedded image


487.691





293
2


embedded image


488.676





294
2


embedded image


514.686





295
2


embedded image


501.718





296
2


embedded image


539.139





297
2


embedded image


504.694





298
2


embedded image


529.729





299
2


embedded image


500.731





300
2


embedded image


565.6





301
2


embedded image


487.691





302
2


embedded image


488.676





303
2


embedded image


557.16





304
2


embedded image


523.672





305
2


embedded image


475.68





306
2


embedded image


480.721





307
2


embedded image


480.721





308
2


embedded image


466.694





309
2


embedded image


528.091





310
2


embedded image


528.091





311
2


embedded image


507.673





312
2


embedded image


460.668





313
2


embedded image


489.664





314
2


embedded image


573.773





315
2


embedded image


506.016





316
2


embedded image


528.091





317
2


embedded image


472.677





318
2


embedded image


460.665





319
2


embedded image


537.546





320
2


embedded image


525.534





321
2


embedded image


491.732





322
2


embedded image


474.693





323
2


embedded image


503.709





324
2


embedded image


503.709





325
2


embedded image


506.759





326
2


embedded image


522.685





327
2


embedded image


508.109





328
2


embedded image


534.721





329
2


embedded image


590.104





330
2


embedded image


487.691





331
2


embedded image


487.691





332
2


embedded image


517.742





333
2


embedded image


499.702





334
2


embedded image


485.719





335
2


embedded image


499.746





336
2


embedded image


487.05





337
2


embedded image


482.675





338
2


embedded image


494.748





339
2


embedded image


492.732





340
2


embedded image


506.759





341
2


embedded image


487.691





342
2


embedded image


486.704





343
2


embedded image


514.758





344
2


embedded image


506.093





345
2


embedded image


518.721





346
2


embedded image


518.721





347
2


embedded image


495.708





348
2


embedded image


507.125





349
2


embedded image


486.704





350
2


embedded image


485.719





351
2


embedded image


522.759





352
2


embedded image


513.699





335
2


embedded image


492.658





354
2


embedded image


489.707





355
2


embedded image


521.771





356
2


embedded image


593.613





357
2


embedded image


481.687





358
2


embedded image


494.082





359
2


embedded image


487.691





360
2


embedded image


520.787





361
2


embedded image


520.787





362
2


embedded image


527.128





363
2


embedded image


463.691





364
2


embedded image


539.139





365
2


embedded image


506.759





366
2


embedded image


486.704





367
2


embedded image


478.001





368
2


embedded image


578.721





369
2


embedded image


472.679





370
2


embedded image


560.731





371
2


embedded image


508.732





372
2


embedded image


492.732





373
2


embedded image


496.696





374
2


embedded image


473.664





375
2


embedded image


514.761





376
2


embedded image


461.656





377
2


embedded image


460.668





378
2


embedded image


471.692





379
2


embedded image


490.053





380
2


embedded image


627.723





381
2


embedded image


478.705





382
2


embedded image


494.748





383
2


embedded image


536.539





384
2


embedded image


520.787





385
2


embedded image


507.673





386
2


embedded image


460.688





387
2


embedded image


472.679





388
2


embedded image


476.026





389
2


embedded image


532.798





390
2


embedded image


506.759





391
2


embedded image


509.113





392
2


embedded image


562.604





393
2


embedded image


492.732





394
2


embedded image


479.69





395
2


embedded image


461.653





396
2


embedded image


526.75





397
2


embedded image


500.712





398
2


embedded image


492.683





399
2


embedded image


504.694





400
2


embedded image


518.721





401
2


embedded image


513.101





402
2


embedded image


460.665





402
2


embedded image


528.091





404
2


embedded image


504.694





405
2


embedded image


472.679





406
2


embedded image


493.717





407
2


embedded image


493.732





408
2


embedded image


497.93





409
2


embedded image


525.112





410
2


embedded image


485.719





411
2


embedded image


505.682





412
2


embedded image


506.137





413
2


embedded image


550.588





414
2


embedded image


534.77





415
2


embedded image


501.718





416
2


embedded image


485.719





417
2


embedded image


489.682





418
2


embedded image


492.732





419
2


embedded image


520.743





420
2


embedded image


517.718





421
2


embedded image


501.718





422
2


embedded image


472.677





423
2


embedded image


542.17





424
2


embedded image


536.561





425
2


embedded image


488.695





426
2


embedded image


506.137





427
2


embedded image


490.667





428
2


embedded image


844.778





429
2


embedded image


513.73





430
2


embedded image


492.732





431
2


embedded image


506.759





432
2


embedded image


542.17





433
2


embedded image


478.656





434
2


embedded image


493.095





435
2


embedded image


478.705





436
2


embedded image


506.137





437
2


embedded image


401.863





438
2


embedded image


498.136





439
2


embedded image


482.071





440
2


embedded image


491.692





441
2


embedded image


493.717





442
2


embedded image


495.708





443
2


embedded image


585.214





444
2


embedded image


544.186





445
2


embedded image


549.162





446
2


embedded image


639.186





447
2


embedded image


493.717





448
2


embedded image


578.642





449
2


embedded image


501.675





450
2


embedded image


499.746





451
2


embedded image


493.095





452
2


embedded image


537.546





453
2


embedded image


491.745





454
2


embedded image


474.668





455
2


embedded image


564.177





456
2


embedded image


585.162





457
2


embedded image


517.718





458
2


embedded image


507.744





459
2


embedded image


491.745





460
2


embedded image


495.708





461
2


embedded image


505.682





462
2


embedded image


510.1





463
2


embedded image


485.719





464
2


embedded image


473.708





465
2


embedded image


510.1





466
2


embedded image


494.082





467
2


embedded image


503.691





468
2


embedded image


495.681





469
2


embedded image


487.691





470
2


embedded image


498.136





471
2


embedded image


507.744





472
2


embedded image


640.67





473
2


embedded image


593.613





474
2


embedded image


614.651





475
2


embedded image


560.108





476
2


embedded image


477.718





477
2


embedded image


459.637





478
2


embedded image


655.685





479
2


embedded image


594.598





480
2


embedded image


676.722





481
2


embedded image


536.561





482
2


embedded image


604.68





483
2


embedded image


578.598





484
2


embedded image


510.1





485
2


embedded image


506.137





486
2


embedded image


507.125





487
2


embedded image


626.687





488
2


embedded image


473.664





489
2


embedded image


528.091





490
2


embedded image


477.718





491
2


embedded image


522.136





492
2


embedded image


506.137





493
2


embedded image


521.546





494
2


embedded image


490.667





495
2


embedded image


485.697





496
2


embedded image


492.008





497
2


embedded image


535.551





498
2


embedded image


481.083





499
2


embedded image


508.109





500
2


embedded image


506.093





501
2


embedded image


477.718





502
2


embedded image


536.163





503
2


embedded image


525.112









Compounds in Table 3 having a basic group or acidic group are depicted and named either as the free base acid or as the salt thereof. Depending on the reaction and purification conditions, the compounds of Table 1 may be isolated in either the free base form, or as a salt (such as HCl salt), or in both free base and salt forms.


The utility of the compounds in accordance with the present invention as inhibitors of β-secretase enzyme activity may be demonstrated by methodology known in the art. Enzyme inhibition is determined as follows.


ECL Assay: A homogeneous end point electrochemiluminescence (ECL) assay is performed using a biotinylated BACE substrate. The Km of the substrate is approximated at 50 μM. A typical reaction contains approximately 0.6 nM enzyme, 0.25 μM of the substrate, and buffer (50 mM Pipes, pH 6.5, 0.1 mg/ml BSA, 0.2% CHAPS, 15 mM EDTA and 1 mM deferoxamine) in a total reaction volume of 100 μl. The reaction proceeds for 1-2 hrs and is then stopped by the addition of 150 μL of a quench cocktail solution (25 μl M Tris-HCl, pH 8.0, 50 μl INC buffer (2% BSA, 0.2% Tween-20 and 0.05% sodium azide diluted in Phosphate buffered saline (PBS) plus 75 μL PBS), containing Streptavidin coated magnetic beads and ruthenylated antibody which specifically recognizes the C-terminal residue of the product. The samples are subjected to M-384 (Igen Inc., Gaithersburg, Md.) analysis. Under these conditions, less than 10% of substrate is processed by BACE 1. The enzyme used in these studies is soluble (transmembrane domain and cytoplasmic extension excluded) human protein produced in a baculovirus expression system. To measure the inhibitory potency for compounds, 10 concentrations of inhibitors are prepared starting from 200 μM with three fold series dilution. Solutions of the inhibitor in DMSO are included in the reaction mixture (final DMSO concentration is 10%). All experiments are conducted at rt using the standard reaction conditions described above. To determine the IC50 of the compound, a four parameter equation is used for curve fitting. The errors in reproducing the dissociation constants are typically less than two-fold.


In particular, the compounds of the following examples had activity in inhibiting the beta-secretase enzyme in the aforementioned assay, generally with an IC50 from about 1 nM to 200 μM. Such a result is indicative of the intrinsic activity of the compounds in use as inhibitors of beta-secretase enzyme activity.


Several methods for preparing the compounds of this invention are illustrated in the Schemes and Examples herein. Starting materials are made according to procedures known in the art or as illustrated herein. The following examples are provided so that the invention might be more fully understood. These examples are illustrative only and should not be construed as limiting the invention in any way.


Exemplary IC50 values for representative compounds of the invention (as decried in the following Examples) are provided below in Table 3.












TABLE 3







Example
IC50(μM)









 3
2.19



 7
22   



 10
20   



 19
0.92



 21
 0.071



 30
14   



 31
 0.024



 38
12   



 44
19   



 77
0.2 



100
0.45










The following abbreviations are used throughout the text:


Me: methyl


Et: ethyl


Bu: butyl


t-Bu: tert-butyl


i-Bu: iso-butyl


Pr: propyl


i-Pr: iso-propyl


Ar: aryl


Ph: phenyl


Bn: benzyl


BOP: benzotriazolyl-N-oxy-tris(dimethylamino)phosphonium hexaflurophosphate


Boc: tert butyloxycarbonyl


TFA: trifluoro acetic acid


THF: tetrahydrofuran


Ac: acetyl


aq: aqueous


rt: room temperature


h: hours


min: minutes

Claims
  • 1. A compound of formula (I)
  • 2. (canceled)
  • 3. A compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein -Q-Y—Z— together forms the groups —N═CR10—CR11═CR10— or —CR10═CR10—CR11═N—, thereby forming a fused pyridyl ring.
  • 4. A compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein -Q-Y—Z— together forms the groups —N═CR10—CR11═N— or —N═CR10—N═CR11—, thereby forming a fused pyrimidinyl ring.
  • 5. A compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein -Q-Y—Z— together forms the groups —NH—CR10═CR10—, —S—CR10═CR10—, —O—CR10═CR10—, —N═CR10—S—, —CR10═CR10═S— or —CR10═CR10—O—, thereby forming a five-membered heteroaryl ring.
  • 6. A compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein X1-X2 is —CR10R11—CR12CR13— and n is 0 or 1.
  • 7. A compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein X1-X2 is —NR12—CR10R11— or —CR10R11—NR12— and n is 1.
  • 8. A compound of any of claim 1, or a pharmaceutically acceptable salt thereof, wherein X1-X2 is —S(═O)pR12—CR10R11— and n is 1.
  • 9. A compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein X1-X2 is —CR10R11—O— or —O—CR10R11—, and n is 1.
  • 10. A compound of claim 1, wherein R1 is selected from the group consisting of (1) hydrogen(2) C1-6alkyl,(3) C3-9 cycloalkyl, or(4) phenyl,wherein said alkyl, cycloalkyl or phenyl R1 moiety is optionally substituted with one or more (a) halo,(b) —OH,(c) —CN,(d) —C1-6 alkyl(e) —C3-6 cycloalkyl, or(f) —O—C1-6 alkyl.
  • 11. A compound of claim 1, wherein R2 is hydrogen and R3 is selected from the group consisting of: (1) hydrogen,(2) aryl, or(3) heteroaryl,wherein said aryl or heteroaryl R3 moiety is optionally substituted with one or more (a) halo,(b) —C1-6 alkyl, wherein said alkyl is optionally substituted with one or more halogen, and(c) —O—C1-6 alkyl.
  • 12. A compound of claim 1, wherein the compound of formula (I) is a compound of formula (II)
  • 13. A compound of claim 1, wherein the compound of formula (I) is a compound of formula (III)
  • 14. (canceled)
  • 15. A compound of claim 1, wherein the compound of formula (I) is a compound of formula (V)
  • 16-21. (canceled)
  • 22. A compound of formula (I)
  • 23. A compound, or a pharmaceutically acceptable salt thereof, said compound or pharmaceutically acceptable salt thereof selected from the group consisting of:
  • 24. A compound, or a pharmaceutically acceptable salt thereof, said compound or pharmaceutically acceptable salt thereof selected from the group consisting of:
  • 25. A pharmaceutical composition, comprising a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
Provisional Applications (1)
Number Date Country
61208172 Feb 2009 US
Divisions (1)
Number Date Country
Parent 13201570 Aug 2011 US
Child 14518825 US